Brighthouse Financial, Inc. (BHFAM) — Council Assessment

🔴 AVOID · Score 32/100 · medium confidence

A deeply leveraged, mark-to-market-driven annuity insurer with a live AM Best negative rating watch — statistically cheap on P/B but too opaque, volatile and instrument-ambiguous for a confident long.

As of 2026-08-02. 11 lenses weighed in, 8 abstained. Sources: 6 filings, 18 news.

360 narrative — news & sentiment digest

Brighthouse Financial (BHFAM/BHF) — Investment Brief

Recent Developments

• AM Best rating action (29 Jul 2026): Rating agency maintains "Under Review with Negative Implications" status for Brighthouse Financial and subsidiaries — suggests potential downgrade.
• Q2 2026 earnings pending: Wall Street expecting earnings growth; company to report imminently (late Jul/early Aug 2026).
• Management transition chatter (21 Jul 2026): Reports of Mark Walters and potential involvement with Guggenheim noted by Seeking Alpha; stock edged lower.
• Stock price weakness: Down ~0.8% to 1.5% over late July; trading around $62–$63.

---

Management Commentary (Earnings Call)

No earnings call transcript provided in materials. Cannot assess guidance, segment performance, margins, or capital allocation at this time.

---

Bull Narrative

• Earnings growth expected: Wall Street consensus anticipates Q2 earnings expansion (EPS ~$4.86 per TradingView preview).
• Valuation multiples available: Forward P/E and EV/revenue metrics published; suggests analyst coverage and potential value positioning.
• Preferred shares actively traded: Multiple depositary share series (Series C, D) showing exchange activity; some retail/institutional interest persists.

---

Bear Narrative

• Negative rating watch: AM Best's "Under Review with Negative Implications" is a material red flag—typically precedes downgrade; signals credit/solvency concerns.
• Implied volatility surge (9 Jul 2026): Options market pricing elevated uncertainty; often reflects fear of earnings miss or guidance cut.
• Management uncertainty: Mid-level chatter about Mark Walters and Guggenheim lack specificity but suggest leadership/strategic questions.
• Stock momentum weak: Multiple small daily declines in late July amid mixed sentiment.

---

Retail Sentiment

Limited forum/Reddit material in the data package. Available sentiment is mixed to cautious:

• Valuation discussions and price-target pieces exist, but no clear bullish thesis emerges.
• AM Best news and IV surge seem to have dampened conviction.

---

Caveats

• No earnings call available: Missing management commentary, guidance, and Q&A—critical for assessing operational health and forward outlook.
• Thin disclosure on rating watch: AM Best action noted but rationale not detailed in materials.
• "Guggenheim/Mark Walters" story underspecified: Seeking Alpha headline vague; no clarity on whether this is M&A rumor, leadership change, or strategic review.
• Preferred share focus: Several headlines focus on depositary preferred shares rather than common equity; different risk/return profile.
• Earnings not yet reported: July 30–31 headlines preview Q2; actual results not in package.

Recommendation: Await Q2 earnings call transcript and AM Best detailed rationale before making tactical moves. The negative rating watch is material and warrants investigation into capital adequacy and reserve adequacy concerns.

Bull case

Optically cheap: P/B ~0.53x on $6.77B book, trailing P/E ~10.7x, and adjusted earnings that are far steadier than GAAP (~$239M Q1 2026 vs $235M Q1 2025, per 10-Q filed 2026-05-07). Graham, Schloss, Marks and Mauboussin all flag genuine statistical cheapness and a possible ratings/technical-driven dislocation. The core insurance-guarantee franchise (regulatory capital, actuarial reserves) is structurally durable and largely AI-resistant (Christensen lens, PASS 72). If equity markets stay stable, rates cooperate, and the AM Best review resolves favorably, adjusted ROE could approach ~12-14% and the equity could re-rate toward book.

Bear case

The dominant council view is caution-to-avoid. GAAP net income is violently erratic ($3.78B 2022, -$1.21B 2023, $331M 2025) and a $792M GAAP net loss in Q1 2026 vs $239M adjusted (10-Q 2026-05-07) shows earnings are a mark-to-market artifact, not operating cash. Leverage is ~35:1 assets-to-equity ($241.8B vs $6.77B). Reinsurance concentration is severe ($19.7B net ceded recoverables, $3.9B unsecured, 84% in top-5, per 10-K 2026-02-24). AM Best 'Under Review with Negative Implications' (narrative, ~29 Jul 2026) is a live downgrade catalyst that for an insurer can trigger surrenders and impair distribution. Book value quality is unverifiable given fair-value MRBs and ULSG rate sensitivity. GAAP ROE ~4.9% is below cost of equity.

Dissent — where the council disagrees

The sharpest split is between the value-screen optimists and the risk desk. Graham (48), Schloss (52), Marks (52) and Mauboussin (42) see real cheapness and possible dislocation value; Druckenmiller (18) and Dalio (28) and Singer (22) call it a hard avoid on regime dependency, unreadable earnings and the negative rating watch. Critically, the two forensic/valuation referees do NOT bless a long: the Valuation Referee ABSTAINED (DCF inapplicable; correct tool is a credit/spread model) and the Short-Seller lands at WATCH (48) citing null FCF, $1B+ GAAP/non-GAAP divergence and non-GAAP dependency. Nearly every quality lens (Buffett, Munger, Akre, Terry Smith) ABSTAINED as outside competence. When the referees won't underwrite value and the risk lenses flag solvency, the cheapness does not earn a clean pass. Compounding everything: BHFAM is the 4.625% non-cumulative Series D preferred depositary share, yet the price/fundamentals ($10.05, 52w high $66.80, P/B 0.53x) appear to describe the common — a fact-base inconsistency multiple lenses flagged that undermines confidence in any precise valuation.

Key risks

• AM Best 'Under Review with Negative Implications' — potential downgrade could trigger surrenders and impair new business (narrative; rationale not in fact base — unverified beyond the headline)
• Extreme leverage (~35:1 assets/equity) means small adverse moves in a $241.8B asset base can wipe the thin $6.77B equity
• Reinsurance counterparty concentration: $19.7B net ceded, $3.9B unsecured, 84% in top-5 reinsurers (10-K 2026-02-24)
• GAAP earnings dominated by MRB/derivative mark-to-market — Q1 2026 GAAP loss $792M vs $239M adjusted (10-Q 2026-05-07); book value quality unverifiable
• Non-cumulative preferred structure: skipped dividends are gone forever, with weak protection and subordination to debt
• ULSG block interest-rate sensitivity; $557M derivative loss in 2024 on rate moves (10-K 2025-02-28)
• Instrument/data ambiguity: BHFAM is the Series D preferred but headline price/valuation metrics appear to reference the common — precise valuation cannot be confirmed

Catalysts

• Resolution of the AM Best review (upgrade/affirm vs downgrade)
• Q2 2026 earnings (pending per narrative) and statutory capital disclosure
• Stabilization or further volatility in equity markets/rates driving MRB and hedge marks
• Management-transition / strategic-review clarity (Guggenheim/Mark Walters chatter per narrative — unverified, underspecified)

DCF valuation

Not applicable: FCF-based DCF is not appropriate for Insurance — banks/insurers are valued on P/B and ROE, REITs on P/FFO and cap rates.

Short-sell evaluation

🚫 AVOID SHORTING

Despite genuine deterioration signals — null FCF, $1B+ quarterly GAAP/non-GAAP divergence, negative rating watch and 35:1 leverage — this is a poor short. The stock/preferred already sits at ~0.53x book after an ~85% collapse from its 52-week high, meaning most of the bad news is priced; the asymmetry favors mean-reversion or ratings resolution over further collapse. Adjusted earnings are actually stable quarter-over-quarter, the equity trades at a deep discount to a (imperfect) book value, and shorting a non-cumulative preferred at a deep discount to par offers little downside room with real squeeze/borrow risk. The referees rate the short only WATCH/abstain — not attractive.

Pros (the short could work)

• Live negative catalyst: AM Best 'Under Review with Negative Implications' could precede a downgrade (narrative)
• Earnings quality is weak: null FCF across all periods, GAAP net income ($331M) exceeds operating cash flow ($259M), $792M GAAP loss in Q1 2026
• Extreme leverage (~35:1) and reinsurance concentration ($3.9B unsecured) create real tail risk in a stress scenario
• Single-regime dependency — bleeds in rising-rate/stagflation environments with no inflation pass-through (Dalio)
• Non-GAAP dependency: investors must trust a management-controlled adjusted-earnings metric

Cons (what kills the short)

• Already down ~85% from 52-week high and trades at ~0.53x book — most bad news likely priced in, limiting downside
• Deep discount to book and to par (for the preferred) means poor risk/reward and thin room to fall further
• Adjusted earnings are stable (~$239M Q1 2026 vs $235M prior year), suggesting the core spread business functions
• Unlimited-downside asymmetry and squeeze/borrow risk on a beaten-down, small-cap name
• Ratings resolution or market stabilization could spark a sharp reversion higher
• Instrument ambiguity (preferred vs common) makes constructing a clean, valid short position operationally risky

Council scorecard

Lens	School	Stance	Score	Conf
AI & Disruption Referee (Christensen-style)	referee	🟢 pass	72	medium
Howard Marks	risk	🟡 watch	52	medium
Walter Schloss	value	🟡 watch	52	medium
Benjamin Graham	value	🟡 watch	48	medium
Forensic Short-Seller (Chanos/Einhorn-style)	referee	🟡 watch	48	medium
Seth Klarman	value	🟡 watch	45	medium
Michael Mauboussin	quality	🟡 watch	42	medium
Ray Dalio	risk	🔴 avoid	28	medium
Paul Singer	value	🔴 avoid	22	medium
Stanley Druckenmiller	risk	🔴 avoid	18	high
Peter Lynch	growth	🔴 avoid	18	medium
Chuck Akre	quality	⚪ abstain	—	high
Warren Buffett	quality	⚪ abstain	—	high
Valuation Referee (Damodaran-style)	referee	⚪ abstain	—	high
Philip Fisher	growth	⚪ abstain	—	high
Joel Greenblatt	value	⚪ abstain	—	high
Bruce Greenwald	value	⚪ abstain	—	high
Charlie Munger	quality	⚪ abstain	—	high
Terry Smith (Fundsmith)	quality	⚪ abstain	—	high

Member reasoning

AI & Disruption Referee (Christensen-style) — 🟢 pass · 72/100 · medium confidence

Brighthouse Financial (BHF/BHFAM) is a large annuity and life insurance company — primarily a capital, actuarial, and regulatory business, not a knowledge-work intermediary or matching/optimization platform. Through the Christensen disruption lens, the core question is: can AI commoditize or disintermediate what BHF does for its customers? The answer is largely no for the core franchise, but with meaningful second-order pressures worth flagging.

BHF's primary product is the manufacturing and guarantee of annuity contracts (variable annuities with GMxBs, Shield index-linked annuities, ULSG life insurance). The scarce, irreplaceable element is the insurer's balance sheet — statutory capital, reserve-backing, and the regulatory license to issue long-duration insurance guarantees. No AI model can substitute for this. A customer buying a guaranteed lifetime withdrawal benefit is buying the PROMISE backed by $241.8B in assets (10-K, filed 2026-02-24) and regulatory capital — that is not a knowledge function AI can replicate or disintermediate. The liability side of an insurance company is structurally AI-resistant: you need licensed capital, actuarial reserves, and a regulated balance sheet.

Distribution risk is more real. BHF sells primarily through independent financial advisors and broker-dealers. If AI-native financial planning tools (think robo-advisors, or hyperscaler-backed planning platforms) reduce advisor reliance or shift product selection toward lower-cost or direct alternatives, BHF's distribution channel could face secular pressure. However, complex annuity products with embedded guarantees are not easily self-served — regulatory requirements, product complexity, and the need for suitability review all slow disintermediation. This is an evolutionary risk (5-10 year horizon) rather than a near-term displacement.

On the cost/tailwind side, AI likely helps BHF modestly: faster underwriting, improved claims analytics, better investment portfolio risk modeling, and lower operational costs. The 10-Q (filed 2026-05-07) notes ongoing exposure to market risk benefits (MRBs) on variable annuities — AI-driven hedging optimization and actuarial assumption modeling could reduce earnings volatility, a genuine tailwind.

The AM Best 'Under Review with Negative Implications' (noted in narrative, July 2026) is a capital-adequacy concern, not a disruption concern — but it reflects the real risk that equity/rate volatility stresses reserves, which is unrelated to AI. The much bigger risk for BHF's earnings is market volatility affecting its derivatives book (Q1 2026 10-Q shows net loss of $792M available to shareholders vs. adjusted earnings of $239M, driven by hedging mark-to-market), not AI displacement.

Management commentary on AI is absent from the fact base (no earnings call transcript available per narrative), so I cannot credit or penalize for honesty about the threat. This limits confidence.

Falsifiable: AI DOES threaten BHF if (1) low-cost AI-native financial planning platforms materially displace traditional advisors who distribute BHF products, causing new sales to shrink, or (2) AI-driven direct-to-consumer insurance platforms obtain regulatory licenses and offer comparable guarantee products cheaper. AI does NOT threaten if (1) advisor channels remain resilient and BHF's Shield/variable annuity sales grow, and (2) AI-driven actuarial/hedging improvements show up as margin stability. The 2-4 year signal to watch is new annuity sales trends and independent advisor channel health.

Key points

• Core insurance guarantee function (balance sheet, regulatory capital, statutory reserves) is structurally AI-resistant — AI cannot substitute for licensed capital backing long-duration obligations
• BHF's $241.8B asset base (10-K, 2026-02-24) and regulatory framework are genuine moats AI cannot commoditize
• AI is a modest tailwind for operational efficiency: actuarial modeling, investment risk analytics, hedging optimization
• Distribution via independent advisors carries some secular disintermediation risk if AI-native planning tools reduce advisor reliance, but complex annuity products slow this materially
• No hyperscaler can 'bundle' an insurance guarantee function — regulatory barriers prevent platform capture
• Second-order positive: rising interest rates and higher-for-longer environment benefits spread income; AI doesn't change this macro driver

Red flags

• No management commentary on AI strategy available (no transcript in fact base) — cannot assess awareness or response
• Advisor/broker-dealer distribution channel could face slow secular pressure from AI-assisted direct financial planning over 7-10 years
• AM Best negative review (narrative, July 2026) signals capital stress — a distracted or capital-constrained management is less able to invest in any technology adaptation
• Earnings are highly volatile due to MRB fair-value marks (Q1 2026 net loss of $792M vs. adjusted earnings of $239M per 10-Q filed 2026-05-07) — this complexity means AI-driven disclosure simplification could eventually raise investor scrutiny of reserve adequacy

Howard Marks — 🟡 watch · 52/100 · medium confidence

BHFAM (Brighthouse Financial depositary preferred shares, 4.625% Series D Non-Cumulative) sits at a price that superficially looks beaten down — the common equity (BHF) is trading around $10 per share, roughly 84-85% below its 52-week high of $66.80 per price data (fundamentals block), while the preferred shares carry a fixed coupon. However, I must be precise: BHFAM is the 4.625% Series D Non-Cumulative Preferred depositary share, not the common. The investment question here is about the fixed-income-like preferred security rather than the equity. Several facts matter for a Marks-style risk assessment. First, on the capital structure: total assets of $241.8B vs. total liabilities of $234.97B yields stockholders' equity of $6.77B (10-K filed 2026-02-24), meaning the company operates with extreme balance sheet leverage — a hallmark of insurance, but the thin equity cushion (~2.8% of assets) means any shock to asset values or reserve estimates flows directly through to solvency. Long-term debt is $3.155B (fundamentals block). The preferred shares (non-cumulative) sit below the debt holders and above common equity — in a stress scenario, non-cumulative means missed dividends do not accrue, so the preferred holder has weaker protection than standard preferred. Second, on earnings quality and volatility: GAAP net income is highly volatile — $1.554B in 2021, $3.775B in 2022, -$1.214B in 2023, $286M in 2024, $331M in 2025 (fundamentals history), and then a Q1 2026 net loss available to shareholders of $792M (10-Q filed 2026-05-07). Adjusted earnings, the non-GAAP measure management uses, are far more stable (Q1 2026 adjusted earnings of $239M vs. Q1 2025 $235M per 10-Q 2026-05-07), but the GAAP volatility reflects massive mark-to-market swings on variable annuity guaranteed benefit riders and derivatives — these are real economic exposures, not just accounting noise. The AM Best 'Under Review with Negative Implications' rating watch (per narrative, dated 29 Jul 2026) is a serious red flag for preferred holders, as it signals potential downgrade, which raises refinancing/capital costs and may trigger regulatory scrutiny. Third, on reinsurance concentration: at December 31, 2025, $19.7B of net ceded reinsurance recoverables exist with third-party reinsurers, of which $16.5B (84%) were with the five largest, including $3.9B unsecured (10-K filed 2026-02-24). This is a meaningful counterparty risk that is hard to handicap from public data. Fourth, on what is priced in: the common equity's collapse from ~$66.80 to ~$10 (84% decline) signals genuine market fear. For the preferred, the 4.625% coupon on a non-cumulative structure in a company under AM Best negative watch and generating volatile GAAP losses is not obviously cheap — the yield must compensate for the non-cumulative skip risk and the structural subordination. Without knowing the current market price of BHFAM precisely relative to par and the redemption features, I cannot fully judge the spread. The last_close of $10.05 on a security that at par is typically $25 represents a significant discount to par — if accurate, the current yield is approximately 11.5% (4.625% x $25 / $10.05), which is a wide spread that might compensate for the risks, and this would represent a potentially attractive distressed-preferred situation in a Marks framework. However, the non-cumulative feature and the AM Best negative watch give me pause. Fifth, the ULSG block risk: the 10-K (2026-02-24) discloses the primary market risk on the ULSG block is future U.S. interest rate levels and bond yields, with significant sensitivity to rate scenarios. Long-term interest rate derivative losses were $557M in 2024 (10-K filed 2025-02-28). This is a real and recurring drag. On AI disruption: for an annuity/life insurer, AI is mildly disruptive at the distribution/underwriting margin but does not fundamentally threaten the core guaranteed-benefit liability franchise over a 3-10 year horizon. Not a primary risk factor here. The situation is genuinely ambiguous — the price has been beaten down severely, there may be real value in the preferred at a deep discount to par, but the non-cumulative structure, AM Best watch, massive GAAP earnings volatility, and $19.7B reinsurance counterparty concentration make this a 'watch carefully' not a clear 'pass.'

Key points

• BHFAM is a 4.625% Non-Cumulative Preferred depositary share currently at $10.05 vs. typical $25 par — implied yield ~11.5% if par is $25, suggesting significant price distress that could attract distressed-income buyers
• Common equity has collapsed ~85% from 52-week high of $66.80 per price data, signaling extreme market fear — a contrarian signal worth probing
• Adjusted earnings stable: Q1 2026 adjusted earnings $239M vs. $235M prior year (10-Q 2026-05-07), suggesting the core underwriting business is functioning despite volatile GAAP results
• Total assets $241.8B, equity $6.77B (10-K 2026-02-24) — thin equity cushion typical of insurance, but means small asset shocks amplify rapidly
• Long-term debt of $3.155B (fundamentals block) plus preferred obligations senior to common; liquidity structure not fully transparent from available filings
• Operating cash flow positive at $259M for 2025 (fundamentals block) — some cash generation is occurring

Red flags

• AM Best 'Under Review with Negative Implications' (narrative, 29 Jul 2026) — potential downgrade is a hard catalyst for preferred holders, raising cost of capital and possibly restricting dividend capacity
• NON-CUMULATIVE preferred: missed dividends do not accrue — if the company skips the 4.625% dividend, holders receive nothing and have no recourse for the missed payment
• GAAP net loss in Q1 2026 of $792M available to shareholders (10-Q 2026-05-07) driven by unfavorable variable annuity and Shield hedge movements — recurring and large mark-to-market risk
• Extreme reinsurance concentration: $19.7B net ceded recoverables, $16.5B (84%) with five largest reinsurers, $3.9B unsecured (10-K 2026-02-24) — counterparty failure would be catastrophic
• ULSG block is materially sensitive to interest rate scenarios; $557M derivative loss in 2024 from interest rate moves (10-K 2025-02-28) demonstrates the real-dollar exposure
• Revenue CAGR -0.52% over 3 years (fundamentals block); business is not growing; declining direct premiums ($1.264B in 2025 vs. $1.499B in 2023 per 10-K 2026-02-24)

Walter Schloss — 🟡 watch · 52/100 · medium confidence

BHFAM (Brighthouse Financial preferred depositary shares, Series D, 4.625% Non-Cumulative) presents a genuinely mixed picture through the Schloss value lens. On the surface, the price-to-book ratio of 0.53x is deeply attractive — this is the kind of statistical cheapness that Schloss sought. The stock (common equity BHF) trades at roughly half of book value ($6.77B stockholders' equity vs. ~$3.6B market cap per fundamentals). However, nearly every other Schloss criterion raises serious concerns that temper the cheapness signal.

FIRST, THE CHEAP PART: Price-to-book of 0.53x (fundamentals block) and price-to-sales of 0.53x are genuinely low in absolute terms. The 52-week range tells a dramatic story — the common trades around $42-67 range per the price block (52w high $66.80, low $42.07), yet the last_close shown is $10.05, which appears to reflect the preferred depositary share (BHFAM = Series D depositary shares, each representing 1/1,000th of a preferred share). The preferred at $10.05 vs. a $25 par depositary share face would itself represent a significant discount, though the fact base does not provide explicit par/liquidation preference detail for this preferred series in the excerpts.

SECOND, THE BALANCE SHEET PROBLEM — CRITICAL FOR SCHLOSS: Total assets of $241.8B vs. total liabilities of $234.97B yields stockholders' equity of only $6.77B (10-K filed 2026-02-24). This is a leverage ratio of approximately 35:1 assets-to-equity. For Schloss, high leverage is a cardinal red flag — it means equity is a thin sliver that can be wiped out by adverse moves in the asset base. Brighthouse's assets are predominantly insurance policy liabilities offset by investment portfolios (mortgage loans $22.76B, policy loans $1.45B per the 10-K) — not the tangible hard assets (inventory, plant, real estate) that Schloss could independently appraise. These are financial assets whose carrying values depend on actuarial assumptions, interest rate models, and fair-value marks.

THIRD, ACCOUNTING COMPLEXITY: The filings (10-K 2026-02-24, 10-Q 2026-05-07) reveal extraordinarily complex accounting: Market Risk Benefits (MRBs) measured at fair value for variable annuity guaranteed minimum benefits (GMxBs), embedded derivatives in Shield Annuities, freestanding derivative hedges, ULSG Statutory Cash Flow Testing reserves, three-month lags on equity method investments. The Q1 2026 10-Q shows a net loss available to shareholders of $792 million driven by 'unfavorable changes in our variable annuity and Shield hedges' despite adjusted earnings of $239 million. This divergence between GAAP and non-GAAP is not the simple balance sheet Schloss could read from filings alone — it is precisely the kind of opacity and hard-to-verify marks he avoided.

FOURTH, EARNINGS VOLATILITY: The historical income record (fundamentals history block) shows wild swings: net income $1.554B (2021), $3.775B (2022), LOSS of $1.214B (2023), $286M (2024), $331M (2025). A net loss in 2023 and persistent derivative-driven volatility is not the stable, boring business Schloss preferred.

FIFTH, AM BEST RATING WATCH: The narrative notes AM Best has placed Brighthouse 'Under Review with Negative Implications' as of July 29, 2026. For an insurance company, a rating downgrade would impair the ability to write new business and could accelerate policyholder lapses — a fundamental threat to franchise value that the cheap book ratio does not compensate for adequately.

SIXTH, REINSURANCE CONCENTRATION RISK: Per the 10-K (2026-02-24), $19.7B of net ceded reinsurance recoverables with third-party reinsurers, with $3.9B unsecured. This is a contingent liability risk that is not reflected in simple book value.

SEVENTH, INSIDER/DIVIDEND DATA: The fact base does not provide insider ownership percentages or details on common dividend payments. The preferred series carries stated coupons (Series D 4.625% non-cumulative), but non-cumulative means missed payments are not owed — adding risk for preferred holders.

AI DISRUPTION ASSESSMENT: AI is not a primary value-driver or threat for this business in the Schloss frame — insurance actuarial work could be enhanced by AI, but Brighthouse's core risk is capital/reserve adequacy and interest rate sensitivity, not technological disruption. Not a material factor here.

SUMMARY: The 0.53x price-to-book is real cheapness by one metric, but the 'book' here is a thin equity cushion sitting atop an enormously leveraged financial institution with complex, hard-to-audit assets. Schloss's framework was built for industrial and commercial companies with tangible, conservatively financed assets — not for life insurance holding companies where book value can evaporate through actuarial assumption changes and derivative mark-to-market. The cheapness is real but not the kind Schloss could trust. Score 52 — a 'watch' rather than avoid only because the discount is genuine, but not a 'pass' because the complexity and leverage violate his core principles.

Key points

• Price-to-book of 0.53x (fundamentals block) is genuinely cheap in absolute terms — meets Schloss's primary statistical screen
• Stock is depressed vs. 52-week history; common BHF 52w high of $66.80 vs. low of $42.07 indicates meaningful price dislocation
• Net income returned to positive in 2024-2025 ($286M and $331M respectively per fundamentals history) after 2023 loss — tentative stabilization
• Stockholders' equity of $6.77B (10-K 2026-02-24) provides nominal book value anchor, though quality of assets is questionable
• Long-term debt of $3.155B (fundamentals) is manageable in isolation, but total liabilities of $234.97B vs. $241.8B total assets means ~35:1 asset/equity leverage

Red flags

• Extreme financial leverage (~35:1 assets/equity per 10-K 2026-02-24) — Schloss's cardinal sin; thin equity cushion can be wiped out by small adverse moves in a $242B asset base
• Opaque, complex accounting: MRBs at fair value, embedded derivatives, ULSG statutory cash flow testing, Shield annuity embedded derivatives — impossible to verify asset quality from filings alone, violating Schloss's 'must understand from filings' criterion
• Wild earnings swings: $3.775B profit (2022) to $1.214B loss (2023) driven by derivative marks, not operational cash flows — unreliable earnings base
• AM Best 'Under Review with Negative Implications' (narrative, July 29 2026) — potential rating downgrade threatens franchise value and new business generation
• Q1 2026 10-Q shows $792M GAAP net loss vs. $239M adjusted earnings — massive gap between reported and non-GAAP figures driven by hedge accounting; Schloss distrusted non-GAAP adjustments
• $19.7B net ceded reinsurance recoverables with $3.9B unsecured (10-K 2026-02-24) — contingent counterparty risk not captured in book value
• No earnings call transcript available; cannot assess management capital allocation, insider ownership, or forward guidance — information gap on key Schloss criteria
• Preferred shares (BHFAM) are non-cumulative — missed dividends are not owed, creating downside risk for preferred holders without the equity upside

Benjamin Graham — 🟡 watch · 48/100 · medium confidence

BHFAM (Brighthouse Financial preferred depositary shares, Series D, 4.625% Non-Cumulative) presents a deeply unusual Graham analysis challenge. The security itself is a preferred depositary share, not common equity, but the fact base is organized around the consolidated enterprise. I will assess the enterprise's Graham-worthiness as the foundation for the preferred claim sitting above common equity in the capital structure.

On price-to-book: The fundamentals block shows stockholders' equity of $6.768 billion against a market cap of approximately $3.556 billion, implying P/B of roughly 0.53x (confirmed in fundamentals block). This is superficially attractive — Graham's rule of thumb requires P/E x P/B under 22.5; at P/E of 10.74x and P/B of 0.53x, the product is approximately 5.7, well inside the threshold. On earnings yield, the P/E of 10.74x implies an earnings yield of ~9.3%, comfortably above any reasonable AAA bond yield.

However, critical Graham red flags dominate: (1) Earnings stability is severely deficient. The five-year history shows net income of $1.554B (2021), $3.775B (2022), -$1.214B loss (2023), $286M (2024), $331M (2025) — a loss year within the look-back period is a categorical Graham disqualifier. (2) The balance sheet structure of an insurance holding company is fundamentally incompatible with Graham's current ratio and working capital tests — total liabilities of $234.967 billion dwarf stockholders' equity of $6.768 billion, a leverage ratio typical of insurers but terrifying by industrial-company standards Graham applied. (3) The 10-Q for Q1 2026 reports a net loss available to shareholders of $792 million driven by unfavorable variable annuity and Shield hedge movements, and adjusted earnings of only $239 million — the GAAP earnings are extremely volatile and sensitive to interest rate and equity market movements that are inherently unpredictable. (4) The AM Best 'Under Review with Negative Implications' rating action (per narrative, July 29 2026) is a material red flag for an insurance enterprise — a potential credit downgrade threatens the operating subsidiaries' ability to write new business and maintain reinsurance relationships. (5) Reinsurance concentration risk is substantial: per the 2025 10-K, $19.7 billion of net ceded reinsurance recoverables exist, with $3.9 billion unsecured and 84% concentrated in five reinsurers — a counterparty failure would be catastrophic. (6) The ULSG block carries material interest rate risk explicitly flagged in both the 2024 and 2025 10-Ks as a primary market risk. (7) No FCF data is available in the fundamentals history, making a conservative earnings power assessment impossible beyond reported GAAP net income.

The preferred share security (BHFAM, 4.625% Series D Non-Cumulative) is non-cumulative, meaning missed dividends are permanently lost — this is a meaningful distinction from Graham's preference for senior, cumulative fixed-income-like securities. The non-cumulative feature eliminates one of the key protections Graham valued in senior securities.

AI/disruption: Not a material near-term factor for the insurance liability runoff business model, though AI could eventually improve actuarial modeling and claims processing; this is not a primary investment consideration here.

Net: The statistical screens (low P/B, modest P/E) are tempting, but the earnings instability, opaque insurance accounting, GAAP losses in Q1 2026, AM Best negative watch, and non-cumulative preferred structure make this a 'watch' rather than a 'pass' — Graham required demonstrated earnings stability above all else, and this enterprise has conspicuously failed that test.

Key points

• P/B of 0.53x and P/E x P/B product of ~5.7x both pass Graham's quantitative thresholds on their face (fundamentals block)
• Earnings yield ~9.3% at 10.74x P/E exceeds AAA bond yields by a comfortable margin
• Common equity book value of $6.768B vs market cap of $3.556B implies substantial discount to book (10-K filed 2026-02-24)
• Net income returned to positive in 2024 ($286M) and 2025 ($331M) after the 2023 loss — trajectory is improving
• $3.155B long-term debt is modest relative to enterprise scale; debt-to-equity of 0.47x is manageable at the holding company level (fundamentals block)

Red flags

• Net loss of $1.214B in 2023 — a loss year within the look-back period is a categorical disqualifier under Graham's earnings stability criterion (fundamentals history)
• Q1 2026 net loss available to shareholders of $792M reported in 10-Q filed 2026-05-07, demonstrating continued extreme GAAP earnings volatility
• AM Best placed company 'Under Review with Negative Implications' as of July 2026 (narrative) — a potential rating downgrade threatens the insurance franchise
• BHFAM is a 4.625% NON-CUMULATIVE preferred — missed dividends are permanently forfeited, eliminating a key protective feature Graham valued in senior securities
• $19.7B net ceded reinsurance recoverables, $3.9B unsecured, concentrated in five reinsurers (2025 10-K) — catastrophic counterparty concentration
• Insurance balance sheet structure (total liabilities $234.967B vs equity $6.768B) makes Graham's current ratio and working capital tests inapplicable and renders book value opaque due to actuarial assumptions
• Variable annuity guaranteed benefit liabilities measured at fair value create extreme P&L volatility tied to equity markets and interest rates, not operating performance
• No free cash flow data available across any reported period — cannot construct a conservative earnings power estimate
• Revenue CAGR of -0.52% over 3 years and no dividend history disclosed for common equity (fundamentals block)

Forensic Short-Seller (Chanos/Einhorn-style) — 🟡 watch · 48/100 · medium confidence

BHFAM (Brighthouse Financial preferred depositary shares / BHF common) is an insurer with a genuinely complex balance sheet, making full forensic work difficult but not impossible. Several warning signs are present and warrant a 'watch' rather than a clear 'pass' or 'avoid.'

EARNINGS vs. CASH: GAAP net income for FY2025 was $331M (10-K filed 2026-02-24) against operating cash flow of only $259M — net income exceeds OCF by ~$72M, a modest but directionally concerning divergence. FCF data is listed as null across all historical periods in the fundamentals block, meaning the quality-of-earnings test cannot be fully run. This is itself a red flag for a forensic lens: an insurer that does not report or cannot easily reconcile FCF to earnings is harder to underwrite. The GAAP earnings history is wildly volatile: $1.554B in 2021, $3.775B in 2022, -$1.214B in 2023, $286M in 2024, $331M in 2025 (fundamentals block). This swing is driven almost entirely by fair-value mark-to-market on variable annuity guaranteed benefit riders (MRBs) and derivative hedges, not by operating cash generation — management explicitly acknowledges this in the 10-Q (filed 2026-05-07) where adjusted earnings of $239M vs. net loss of $792M for Q1 2026 alone illustrates the enormous and persistent GAAP vs. non-GAAP divergence.

NON-GAAP RELIANCE: The company's primary management metric is 'adjusted earnings,' which strips out changes in MRB fair values, net derivative gains/losses, and investment gains/losses. Q1 2026: GAAP net loss of $792M vs. adjusted earnings of $239M — a $1.031B gap in a single quarter (10-Q filed 2026-05-07). This is structural, not occasional. While standard in the annuity industry, the sheer magnitude of the divergence means GAAP earnings are essentially uninformative as an earnings quality test, and investors must fully rely on management's non-GAAP construct. Chanos would flag this: the metric you need to trust is the one management controls the inputs to.

BALANCE SHEET OPACITY: Total assets of $241.8B vs. stockholders' equity of $6.768B (fundamentals block, 2025-12-31) — a leverage ratio of ~35x. The majority of assets are policyholder-linked and subject to actuarial and fair-value assumptions. Reinsurance recoverables of $19.7B with $3.9B unsecured (10-K filed 2026-02-24) represent a meaningful counterparty concentration risk; 84% of net ceded recoverables sit with the five largest reinsurers.

MARKET RISK BENEFIT (MRB) COMPLEXITY: Variable annuity guaranteed minimum benefits are classified as MRBs measured at fair value (10-K filed 2026-02-24, 10-Q filed 2026-05-07). Changes in these flow through GAAP P&L. The ULSG (universal life secondary guarantee) block carries specific interest-rate risk the company manages through derivatives, with a $557M derivative loss on interest rate moves in 2024 alone (10-K filed 2025-02-28). This creates a business where reported GAAP earnings are primarily a function of capital markets moves rather than underwriting or operating performance — classic earnings-quality concern.

AM BEST RATING WATCH: The narrative digest (dated as of 2026-08-02) notes AM Best has placed BHF 'Under Review with Negative Implications' — a potential precursor to a rating downgrade. For an insurer, a ratings downgrade is a hard catalyst: it raises cost of capital, can trigger policyholder surrender activity, and may restrict distribution relationships. The detailed rationale is not provided in the fact base so severity cannot be precisely assessed, but this is a material red flag.

PRICE ANOMALY: The fact base shows last_close of $10.05 for BHFAM yet the 52-week range is $42.07-$66.80 and the narrative discusses the stock trading at $62-$63. BHFAM is the ticker for the Series D preferred depositary shares (4.625% non-cumulative), confirmed by the 8-K filings listing BHFAM as 'Depositary Shares, each representing a 1/1,000th interest in a share of 4.625% Non-Cumulative Preferred Stock, Series D.' The $10.05 price with a 52-week high of $66.80 is internally inconsistent — these figures may belong to the common stock (BHF) rather than the preferred. This data discrepancy means some valuation metrics (P/E of 10.74x, P/B of 0.53x, market cap of $3.556B) in the fundamentals block appear to reference common equity, not the preferred instrument. I cannot reliably assess the preferred's own valuation without cleaner data.

KILL QUESTION: The bear case crystallizes around: (1) AM Best downgrade materializing, triggering surrender/distribution disruption; (2) an adverse capital markets scenario (equity market decline or rate spike) that causes MRB losses to overwhelm adjusted earnings, impairing statutory capital and restricting dividends to the holding company; (3) reinsurance counterparty stress on the $3.9B unsecured recoverable; (4) ULSG reserve adequacy in a sustained low-rate environment. The bull case (disproof) is stable equity markets, rising rates, and continued regulatory capital adequacy — in which adjusted earnings of ~$235-$239M per quarter look reasonable relative to current valuation.

AI DISRUPTION: Not a material near-term factor for this business. AI may improve actuarial modeling efficiency and fraud detection but is unlikely to disintermediate the annuity/insurance distribution model within a 3-5 year horizon. Not a primary driver of the forensic thesis here.

Missing data: No Form 4 insider selling data, no Q2 2026 earnings, no detail on covenant structures for the $3.155B long-term debt, no AM Best rationale, no FCF history, no earnings call transcript. These gaps reduce confidence from high to medium.

Key points

• GAAP net income ($331M, FY2025) exceeds operating cash flow ($259M) — earnings outpacing cash, per fundamentals block
• Massive structural GAAP vs. non-GAAP divergence: Q1 2026 GAAP net loss $792M vs. adjusted earnings $239M — a $1.031B single-quarter gap (10-Q filed 2026-05-07)
• GAAP earnings are driven by MRB fair-value marks and derivative P&L, not operating cash — management's own adjusted earnings metric is the only meaningful lens, creating non-GAAP dependency risk
• Balance sheet leverage ~35x (total assets $241.8B vs. equity $6.768B per fundamentals); $19.7B reinsurance recoverables with $3.9B unsecured (10-K filed 2026-02-24)
• AM Best 'Under Review with Negative Implications' is a hard potential catalyst for ratings downgrade, which for an insurer can impair distribution and trigger surrender activity (narrative digest, 2026-08-02)
• BHFAM ticker appears to be the Series D 4.625% preferred depositary shares per SEC filings, but price/fundamentals data in fact base seems to reference common equity — data inconsistency clouds the precise instrument being analyzed
• FCF not reported for any period in the fact base — eliminates the primary forensic earnings-quality test

Red flags

• Persistent GAAP earnings volatility driven by fair-value accounting, not cash operations — 5-year net income swings from +$3.775B to -$1.214B are almost entirely mark-to-market
• Non-GAAP 'adjusted earnings' diverges from GAAP by over $1B in a single quarter; management controls the key inputs to the metric investors must rely on
• $3.9B of reinsurance recoverables are unsecured (10-K filed 2026-02-24) — counterparty risk in a stress scenario
• AM Best negative review watch — potential downgrade catalyst not yet resolved (narrative digest)
• FCF history entirely absent from fact base — cannot run the core earnings-quality test that is the foundation of forensic short analysis
• Possible ticker/data mismatch: BHFAM is a preferred depositary share, not common equity, but the fundamentals block appears to report common equity metrics — investor confusion risk
• ULSG block subject to significant interest rate risk; $557M derivative loss in 2024 alone from rate moves (10-K filed 2025-02-28)

Seth Klarman — 🟡 watch · 45/100 · medium confidence

BHFAM (Brighthouse Financial preferred depositary shares, 4.625% Series D Non-Cumulative) trades at $10.05 against a 52-week high of $66.80 — an 85% decline that demands investigation as a potential forced-selling, orphaned-security opportunity. However, my framework demands I assess this instrument on its own terms with strict downside discipline.

First, a critical clarification: the fact base conflates the symbol BHFAM (Series D preferred depositary shares, 4.625% non-cumulative) with the common equity (BHF). The price of $10.05 vs. a 52-week high of $66.80 is anomalous for a preferred instrument unless it has been deeply impaired. The narrative references a trading range of $62-$63, suggesting the price data in the structured fields ($10.05) may pertain to the preferred share trading at a steep discount to par or face value, while the common trades much higher. This ambiguity is a significant data quality problem that prevents a high-confidence verdict.

Assuming BHFAM is indeed the 4.625% Series D preferred trading around $10 (deeply below any reasonable par/liquidation value if par is $25 per depositary share), the margin-of-safety question centers on: (1) can Brighthouse honor preferred dividends, and (2) what is the liquidation priority?

From the 10-K (filed 2026-02-24, period 2025-12-31): total assets $241.8B, total liabilities $234.967B, stockholders' equity $6.768B. Book equity per common share implies ~$118/share on 57.18M shares. Long-term debt is only $3.155B (debt-to-equity 0.47 per fundamentals). These headline numbers look supportive of preferred coverage at first glance.

However, the red flags for Klarman-style analysis are severe: (a) The 10-Q (filed 2026-05-07) shows Q1 2026 net loss available to shareholders of $792M, driven by 'unfavorable changes in variable annuity and Shield hedges'; GAAP earnings are wildly volatile — 2021: +$1.554B, 2022: +$3.775B, 2023: -$1.214B, 2024: +$286M, 2025: +$331M. This volatility is precisely the kind of complexity that masks whether book value is real or mark-to-model fiction. (b) The adjusted earnings metric ($239M in Q1 2026 vs. $792M GAAP loss) is a management non-GAAP construct that strips out the very derivatives and hedging losses that define the company's actual economic exposure. I cannot rely on adjusted earnings as a floor. (c) Reinsurance recoverables: $19.7B net ceded with third parties, of which $3.9B unsecured (per 10-K 2026-02-24) — these are contingent assets that may not survive a reinsurer stress. (d) AM Best 'Under Review with Negative Implications' (per narrative, 29 Jul 2026) is a material downgrade signal for an insurance company — it directly threatens statutory capital adequacy, policyholder confidence, and the ability to write new business. For a non-cumulative preferred, a downgrade path could lead to dividend suspension with no make-whole obligation. (e) Variable annuity GMxB liabilities measured at fair value introduce enormous mark-to-model sensitivity; the company acknowledges in filings that these are affected by 'broad range of capital markets scenarios.' (f) ULSG block risk: the 10-K explicitly warns about insufficient assets to meet ULSG obligations under adverse interest rate scenarios.

The 4.625% non-cumulative structure is particularly punishing from a Klarman perspective: if dividends are suspended, they are GONE — no accrual, no catch-up. This is not a distressed bond with hard claims; it is junior to policyholders, general creditors, and senior debt holders, and sits above only common equity in a very thin equity cushion relative to $234.967B in liabilities.

Price-to-book of 0.53x on common equity is superficially cheap, but insurance book value is notoriously unreliable when derivatives, embedded guarantees, and reinsurance recoverables dominate the balance sheet. The 'floor' I need for a margin of safety may be much lower than stated book.

On AI disruption: not a primary driver here. Insurtech could affect distribution costs and underwriting efficiency, but Brighthouse's variable annuity and life insurance blocks are long-tail, relationship-driven products unlikely to be rapidly disintermediated. AI risk is not a near-term impairment to this thesis.

Net assessment: The deep price dislocation creates optionality but not a clear margin of safety. The non-cumulative structure, complex derivative/guarantee liabilities, AM Best negative watch, and GAAP earnings volatility prevent me from establishing a reliable conservative intrinsic value floor. I cannot confirm the downside is protected. This is a 'watch' — the dislocation is real and may be partly technical/ratings-driven, but the instrument-level risk is too opaque for a 'pass' without more data on statutory capital ratios, the AM Best rationale, and actual par/liquidation terms of BHFAM.

Key points

• Price of $10.05 vs. 52-week high of $66.80 suggests extreme dislocation — warrants investigation as potential forced-selling or ratings-driven orphan situation
• Common equity book value ~$6.768B on 57.18M shares (per 10-K 2026-02-24) gives P/B of 0.53x, superficially cheap, but insurance book quality is highly uncertain given derivatives and guarantee liabilities
• Adjusted earnings stable (~$239M Q1 2026, $235M Q1 2025 per 10-Q 2026-05-07) but GAAP swings wildly — cannot use adjusted earnings as a reliable cash flow floor
• Long-term debt only $3.155B against total assets of $241.8B; balance sheet leverage in traditional sense appears manageable
• AM Best 'Under Review with Negative Implications' (narrative, 29 Jul 2026) is a potential catalyst for forced institutional selling — classic Mr. Market dislocation signal worth monitoring
• AI/tech disruption not a primary near-term risk to this business model

Red flags

• BHFAM is 4.625% NON-CUMULATIVE preferred — dividend suspension carries no make-whole obligation, destroying the income floor that would justify a distressed price
• AM Best negative watch (narrative 29 Jul 2026) directly threatens statutory capital standing and policyholder confidence — impairment risk is real, not just technical
• Q1 2026 GAAP net loss of $792M (10-Q filed 2026-05-07) driven by variable annuity/Shield hedge losses — earnings are volatile and unpredictable, masking true economic exposure
• $19.7B net ceded reinsurance recoverables with $3.9B unsecured (10-K 2026-02-24) — contingent asset subject to reinsurer credit risk
• Variable annuity GMxB liabilities measured at fair value introduce mark-to-model uncertainty; book equity floor may be significantly overstated under stress
• ULSG block explicitly flagged as at risk under adverse interest rate scenarios (10-K 2026-02-24 and 2025-02-28) — potential reserve shortfall
• Data ambiguity: $10.05 price vs. $62-63 narrative price creates fact-base inconsistency; cannot confirm which price is correct for BHFAM preferred, undermining the valuation analysis
• No earnings call transcript available; management commentary on capital position, regulatory capital ratios, and AM Best dialogue is entirely missing

Michael Mauboussin — 🟡 watch · 42/100 · medium confidence

Brighthouse Financial (BHF/BHFAM) is an insurance holding company primarily in annuities — specifically variable annuities with guaranteed minimum benefits (GMxBs) and Shield (indexed) annuities. The Mauboussin framework applies but with important caveats: ROIC analysis for an insurer translates primarily to ROE and spread analysis, and the moat question centers on whether the company earns persistently above its cost of equity capital. The evidence is mixed and the picture is substantially clouded by accounting complexity. On valuation, the stock trades at 0.53x book (per fundamentals block) and ~10.7x trailing GAAP P/E, suggesting the market embeds very low expectations — potentially too low if the franchise has durable earnings power, but the embedded skepticism appears partially warranted given the operating volatility. ROE for 2025 is reported at 4.9% (fundamentals: net_income $331M on equity $6,768M), which is almost certainly below any reasonable cost of equity for an insurer (typically 9-12%). However, management's non-GAAP 'adjusted earnings' strip out the mark-to-market noise from derivatives and MRBs — Q1 2026 adjusted earnings of $239M annualize to roughly ~$960M, which on $6.8B equity would imply an adjusted ROE closer to 14%, potentially above cost of equity. This divergence between GAAP and adjusted is the central interpretive challenge. The moat analysis is sobering: (1) Scale economies exist but are not dominant — annuity distribution is intermediary-driven through brokers/advisors, limiting direct pricing power; (2) Switching costs are moderate — annuity surrender charges create some lock-in but duration is finite; (3) No meaningful network effects; (4) Brand/intangibles are weak — BHF was spun from MetLife in 2017 and lacks a distinctive consumer brand; (5) The competitive advantage in variable annuities is partly structural (regulatory capital requirements create barriers to entry) but also partly the ability to hedge complex GMxB liabilities — a technically demanding capability that is genuinely rare. The 10-K (filed 2026-02-24) discloses $19.7B in net ceded reinsurance recoverables, with $3.9B unsecured — a concentration risk that limits the moat's durability. The ULSG block (universal life secondary guarantee) is a legacy liability with significant interest rate sensitivity, as the 10-K notes; rising rates hurt via derivatives losses but falling rates threaten reserving adequacy. Q1 2026 10-Q shows a net loss of $792M (GAAP) for the quarter on derivative/MRB mark-to-market, with adjusted earnings of $239M — this divergence illustrates the expectations problem: what is the 'real' earning power? The AM Best 'Under Review with Negative Implications' (per narrative, 29 Jul 2026) is a material red flag — it signals potential downgrade which would increase cost of funds, restrict distribution, and impair capital position. This is the single most important near-term catalyst and it is negative. Expectations embedded in price: at 0.53x P/B, the market implies either persistent sub-cost-of-equity ROE or capital impairment risk. For expectations to be 'too low,' adjusted earnings must prove durable (~$900M-$1B annually), hedging must work through a cycle, and the AM Best situation must resolve favorably. That is a plausible but uncertain scenario. From a distribution standpoint: bear scenario (~30% probability) — AM Best downgrades, capital pressure forces equity raise or dividend cut, book value erodes, stock falls further; base (~45%) — adjusted earnings hold, AM Best concern resolves, stock re-rates modestly toward book; bull (~25%) — hedging performance improves, adjusted ROE expands above 12%, re-rating to 0.7-0.8x book. The fat tail risk is clearly on the downside given the rating watch. Revenue CAGR is essentially flat (-0.5% over 3 years per fundamentals), net income is extremely volatile ($3.8B in 2022, -$1.2B in 2023, $286M in 2024, $331M in 2025), confirming that GAAP results are dominated by market movements rather than underlying business economics. AI/technology disruption is not a primary near-term driver here — the moat is regulatory/actuarial, not technological. However, AI could over a 5-10 year horizon improve underwriting, reduce costs in policy administration, and potentially enable new entrants to compete more effectively on pricing — a mild negative for the moat trajectory. The moat is rated Narrow with a Stable-to-Eroding trajectory. The capital allocation picture is opaque given the regulatory structure, but the preferreds and subordinated debentures (BHFAM is the 4.625% Series D preferred depositary shares) represent a senior claim on earnings — from a common equity Mauboussin perspective, the preferred structure absorbs some upside. Overall: the expectations are genuinely low but not unambiguously too low given real risks. Score 42 — watch, not pass.

Key points

• P/B of 0.53x implies market expects sub-cost-of-equity ROE persistently; GAAP ROE for 2025 of ~4.9% confirms this fear (fundamentals block: $331M net income / $6,768M equity)
• Adjusted earnings (non-GAAP) of $239M in Q1 2026 vs. GAAP loss of $792M (10-Q filed 2026-05-07) illustrates the core interpretive challenge — underlying economics may be better than GAAP suggests, but adjusted earnings strip out real economic risks from derivatives and MRBs
• Moat rated Narrow: regulatory capital barriers limit new entry to variable annuity GMxB market, and hedging expertise is genuinely complex, but distribution is intermediary-driven (limiting pricing power) and brand is weak (MetLife spinoff 2017)
• Revenue effectively flat over 3 years (-0.5% CAGR) with violent net income swings driven by mark-to-market, not operational deterioration or improvement — separating skill from luck/market is very difficult
• AM Best 'Under Review with Negative Implications' (narrative, 29 Jul 2026) is the highest-urgency negative catalyst; a downgrade would materially impair distribution access and increase cost of capital
• $19.7B net ceded reinsurance recoverables with $3.9B unsecured at Dec 31 2025 (10-K filed 2026-02-24) represents a meaningful counterparty concentration risk that caps franchise durability
• Switching costs exist via surrender charges on annuities but are finite and declining over the policy lifetime — not a durable compounding moat source

Red flags

• AM Best negative rating watch (narrative 29 Jul 2026) — potential downgrade is a near-term capital and franchise threat that could be self-reinforcing
• GAAP ROE of ~4.9% for 2025 is almost certainly below cost of equity (~9-11% for insurance), meaning on GAAP metrics the company is destroying shareholder value
• Extreme net income volatility (2021: $1.6B, 2022: $3.8B, 2023: -$1.2B, 2024: $286M, 2025: $331M per fundamentals history) makes it nearly impossible to identify durable skill vs. market-driven luck
• ULSG block carries material interest rate risk — 10-K (2026-02-24) explicitly flags that interest rate uncertainty could mean insufficient assets to meet future policyholder obligations
• No FCF data available (fundamentals history shows null FCF for all years); operating cash flow of only $259M in 2025 on $241.8B total assets signals very thin cash generation relative to balance sheet size
• Management transition chatter (narrative, 21 Jul 2026) adds leadership uncertainty at a moment when strategic clarity is most needed
• The 52-week high/low discrepancy in the fact base is internally inconsistent — price shows $10.05 last close but 52w high of $66.80, while narrative references stock trading ~$62-63; this likely reflects the BHFAM preferred ticker vs. common BHF, creating ambiguity about which security is actually being assessed

Ray Dalio — 🔴 avoid · 28/100 · medium confidence

Brighthouse Financial (BHFAM — the 4.625% Non-Cumulative Preferred Stock, Series D depositary shares) is deeply applicable to my macro/balance-sheet framework because it is fundamentally a rate-sensitive, long-duration liability insurer with embedded derivative complexity and a business model that is acutely single-regime dependent. My assessment is a clear avoid.

REGIME ROBUSTNESS: Brighthouse's core business — variable annuities with guaranteed minimum benefit (GMxB) riders and universal life with secondary guarantees (ULSG) — is highly sensitive to the interest rate and equity market regime. From the 10-K (filed 2026-02-24), the company explicitly states the primary market risk in ULSG is 'uncertainty around future levels of U.S. interest rates and bond yields.' The 10-Q (filed 2026-05-07, period 2026-03-31) shows that Q1 2026 produced a net loss available to shareholders of $792 million driven by 'unfavorable changes in variable annuity and Shield hedges.' The 2024 10-K shows a $557 million loss from ULSG interest rate derivatives in 2024 alone when long-term rates rose. This business wins in a falling-rate, stable-equity environment and bleeds in stagflation or rising-rate regimes — a single-regime dependency that is the core of my concern.

BALANCE SHEET RESILIENCE: Total assets of $241.8B against total liabilities of $234.97B leaves stockholders' equity of only $6.77B (fundamentals data), implying extreme balance-sheet leverage at roughly 35:1 assets-to-equity. Long-term debt stands at $3.155B. The 10-K (2026-02-24) discloses $19.7B of net ceded reinsurance recoverables with third-party reinsurers, of which $3.9B is unsecured — a significant counterparty concentration risk. The five largest reinsurers hold 84% of net ceded recoverables ($16.5B). This is a massive hidden tail risk: a reinsurer failure in a stress scenario (exactly the environment where you need the coverage) would be catastrophic.

RATE SENSITIVITY: The ULSG block's sensitivity to interest rates is explicitly and repeatedly flagged in filings. The 2024 10-K notes the company lost $557M on ULSG interest rate derivatives when long rates rose in 2024 and lost $197M when they rose less in 2023. The Q1 2026 10-Q notes further losses from 'unfavorable changes in variable annuity and Shield hedges.' In a higher-for-longer or stagflationary regime, this business faces dual headwinds: mark-to-market losses on hedges AND reserving pressure on guaranteed liabilities. There is no natural inflation pass-through — the guaranteed benefits are nominal commitments.

CREDIT/RATING RISK: The narrative digest (as of Aug 2026) flags AM Best maintaining 'Under Review with Negative Implications' — a material signal of potential downgrade. For a preferred share issuer, a ratings downgrade is existential for cost of capital and regulatory standing. The fact base does not provide AM Best's detailed rationale, but the direction is unambiguous.

NARRATIVE STOCK PRICE ANOMALY: The price data shows BHFAM last close at $10.05 against a 52-week high of $66.80 — an 85% decline from peak (price data). The narrative references the stock trading at '$62-$63' which appears inconsistent with the $10.05 close for BHFAM (the preferred depositary shares), suggesting the narrative may conflate BHF common stock with BHFAM preferred. Either way, the 52-week range collapse is severe and warrants caution.

DEBT CYCLE POSITION: The annuity business is deeply tied to baby-boomer wealth accumulation funded by decades of credit expansion and rising financial asset values. A deleveraging cycle or sustained equity bear market directly impairs account values, increases the in-the-money probability of guaranteed benefit riders, and pressures statutory capital — precisely the scenario where the insurer is most stressed.

AI/DISRUPTION: AI is a secondary factor here relative to macro risks, though it may modestly help with actuarial modeling and underwriting efficiency. It does not resolve the fundamental rate/regime sensitivity of the liability structure.

DIVERSIFICATION VALUE: For a portfolio, this preferred share adds exposure to insurance-sector credit risk, interest rate duration, and equity market volatility — all correlated to the same risk-off scenarios that would stress most equity holdings. The diversification benefit is minimal.

CONCLUSION: A 35:1 leveraged balance sheet, single-regime earnings dependence, $3.9B of unsecured reinsurance counterparty exposure, persistent ULSG rate-derivative losses, AM Best negative rating watch, and no inflation pass-through on long-duration nominal guaranteed liabilities make this a high-risk, low-regime-robustness security that fails nearly every criterion in my framework.

Key points

• Single-regime dependency: business model profits only in falling-rate, stable-equity environments; bleeds in stagflation or sustained rising-rate regimes (ULSG derivative losses of $557M in 2024 per 10-K filed 2026-02-24)
• 35:1 asset-to-equity leverage ($241.8B assets vs $6.77B equity per fundamentals) with $19.7B reinsurance recoverables, $3.9B unsecured, concentrated in 5 reinsurers (10-K filed 2026-02-24)
• AM Best 'Under Review with Negative Implications' per narrative digest — material downgrade risk for a preferred share issuer
• Q1 2026 net loss of $792M driven by variable annuity and Shield hedge losses (10-Q filed 2026-05-07); GAAP earnings highly volatile and unreliable as regime signal
• No inflation pass-through: guaranteed nominal benefits on annuities and ULSG policies are fixed-dollar commitments that erode insurer margin in inflationary regimes
• BHFAM 52-week range $42.07–$66.80 vs $10.05 current close — 85% decline from peak signals severe market dislocation in this security class
• Adjusted earnings (non-GAAP) of $239M in Q1 2026 vs GAAP net loss of $792M — massive divergence signals derivative/hedging complexity that obscures true economic earnings

Red flags

• $3.9B of unsecured reinsurance recoverables represent a single-point-of-failure tail risk in a credit stress scenario (10-K filed 2026-02-24)
• ULSG block explicitly identified as subject to interest rate uncertainty; $557M derivative loss in 2024 when rates rose (10-K filed 2024-12-31)
• AM Best negative rating watch per narrative — potential ratings downgrade threatens preferred dividend sustainability and regulatory capital standing
• Revenue CAGR of -0.52% over 3 years with net income swinging from $3.775B (2022) to -$1.214B (2023) to $331M (2025) — extreme earnings volatility inconsistent with stable preferred coverage
• BHFAM price collapse from ~$66 52-week high to $10.05 suggests market is pricing meaningful distress probability in this preferred security
• Operating cash flow of only $259M against $3.155B long-term debt and large derivative book — thin cash generation relative to obligations
• No FCF data available in fact base; FCF-based valuation deemed not applicable by valuation block — cannot assess true cash generation quality

Paul Singer — 🔴 avoid · 22/100 · medium confidence

BHFAM (the 4.625% Non-Cumulative Preferred Stock, Series D depositary shares of Brighthouse Financial) is being assessed here, but the broader activist lens must be applied to the underlying company, Brighthouse Financial, Inc. (BHF/common). From an Elliott-style activist perspective, BHF presents a deeply problematic profile: the business is a heavily regulated life insurance company with $241.8B in total assets but only $6.8B in stockholders' equity (as of 10-K filed 2026-02-24), meaning the equity layer is extraordinarily thin relative to the balance sheet. The 'self-help gap' is difficult to define and even harder to close in a regulated insurer — actuarial reserving, state insurance regulation, and capital requirements constrain almost every lever an activist would reach for. The stock price data in the fact base is internally inconsistent: the price shows $10.05 (which appears to be the preferred share BHFAM trading around par/liquidation value for a $25-par depositary preferred), while the narrative references common stock trading at $62-63. The 52-week range of $42.07-$66.80 aligns with the common equity narrative, not a $10 preferred. This data inconsistency weakens confidence in the price-based analysis. Setting that aside and examining the underlying company: (1) Net income is highly volatile — $1.55B (2021), $3.78B (2022), -$1.21B (2023), $0.29B (2024), $0.33B (2025) per fundamentals history — driven by mark-to-market swings on variable annuity guaranteed benefit riders and derivatives, not operational instability per se, but making normalized earnings nearly impossible to pin down without full actuarial data. (2) The 10-Q filed 2026-05-07 shows Q1 2026 net loss available to shareholders of $792 million versus adjusted earnings of $239 million — the GAAP vs. non-GAAP divergence is enormous, driven by variable annuity and Shield hedges. This is not the kind of clean 'margin gap vs. peers' story Elliott typically runs. (3) Reinsurance concentration risk is severe: per 10-K filed 2026-02-24, $19.7B of net ceded reinsurance recoverables with third-party reinsurers, of which $3.9B unsecured — a single reinsurer failure could be catastrophic, and no activist can fix that. (4) The AM Best 'Under Review with Negative Implications' (per narrative, 29 Jul 2026) is a material credit red flag — if downgrades follow, policyholder confidence and new business flows could be impaired, destroying franchise value before any activist thesis can play out. (5) The capital structure includes $3.155B in long-term debt plus multiple preferred series (Series A at 6.600%, Series B at 6.750%, Series C at 5.375%, Series D at 4.625%, and 6.250% Junior Subordinated Debentures due 2058 per the 8-K filings) — the equity has multiple layers ahead of it and the preferred itself is non-cumulative, meaning dividends can be suspended without default. (6) P/B of 0.53 looks cheap on the surface but is essentially meaningless for a life insurer with enormous actuarial liabilities embedded in book value — the 'true' book value depends entirely on discount rate and mortality assumptions that no outside activist can audit. (7) The 'lever' question: no dual-class structure is evident from the filings (the 8-K annual meeting results show a single common share class), and boards are annually elected (per 8-K filed 2026-06-03, all nine directors elected for one-year terms). This is a positive governance feature. However, an activist pushing for asset sales, spin-offs, or major capital return in a state-regulated insurer faces an entirely different regulator — state insurance commissioners who must approve any material transactions. This regulatory chokepoint is perhaps the most significant 'no lever' red flag in the entire analysis. The gap, even if real, is not forceable in the way Elliott would require. (8) AI disruption: insurance distribution and underwriting are increasingly AI-susceptible on the distribution side, but Brighthouse's core business is managing legacy variable annuity guarantees — a closed block of actuarial obligations that AI cannot transform. Not a near-term material factor either way. The combination of regulatory barriers to activist intervention, volatile and opaque earnings driven by mark-to-market accounting, AM Best negative watch, massive reinsurance concentrations, and a GAAP loss of $792M in Q1 2026 despite adjusted earnings of $239M makes this a clear avoid under my framework. There is no clean segment to spin, no identifiable capital allocation fix that a regulator would allow, and no obvious floor independent of the AM Best/regulatory outcome.

Key points

• P/B of 0.53 appears cheap but is misleading for a life insurer — book value embeds actuarial liabilities whose true value depends on discount rate and mortality assumptions opaque to outsiders (10-K 2026-02-24)
• Annual board elections confirmed (8-K 2026-06-03) — no staggered board, which is a positive governance feature, but state insurance regulators act as an effective veto on any material activist-driven transaction
• Adjusted earnings relatively stable at ~$239M Q1 2026 and ~$235M Q1 2025 (10-Q 2026-05-07), suggesting the underlying insurance spread business is functional, but GAAP net loss of $792M in same quarter shows the extreme mark-to-market noise that makes any clean activist narrative nearly impossible to construct
• $19.7B net ceded reinsurance recoverables at Dec 31 2025, with $3.9B unsecured (10-K 2026-02-24) — tail risk concentration that no activist can restructure away
• AM Best 'Under Review with Negative Implications' (narrative, 29 Jul 2026) represents a potential downgrade that would precede, not follow, any activist resolution — destroys the timeline
• Multiple preferred series and $3.155B long-term debt plus 6.250% Junior Subordinated Debentures due 2058 create a complex capital stack that constrains equity optionality

Red flags

• Regulatory chokepoint: state insurance commissioners must approve material transactions — the primary activist lever (sell, spin, recapitalize) is effectively blocked without regulatory consent, making any thesis non-forceable
• Gap is not clearly closeable: underperformance in GAAP earnings driven by mark-to-market on GMxB riders and derivatives — this is a structural accounting feature, not a management choice, and no new owner changes it
• AM Best negative watch (narrative) threatens franchise value — a downgrade could impair new business and statutory capital before an activist could build a position and act
• Q1 2026 GAAP net loss of $792M versus adjusted earnings of $239M (10-Q 2026-05-07) — the divergence is so large that it indicates the business runs primarily on non-GAAP metrics, making outside valuation of the activist gap nearly impossible to validate
• No identifiable sum-of-the-parts opportunity: Brighthouse is a single-segment life/annuity insurer without clean separable divisions evident from the available filings; no spinnable segment with independent value
• Non-cumulative preferred structure (Series D BHFAM) means preferred dividends can be suspended without a default event — the preferred itself has no enforcement mechanism that creates activist leverage
• Data inconsistency in the fact base: price shown as $10.05 with 52-week range $42.07-$66.80 is internally inconsistent, suggesting the $10.05 reflects the preferred share value while the range reflects common equity — undermines confidence in quantitative analysis

Stanley Druckenmiller — 🔴 avoid · 18/100 · high confidence

BHFAM (Brighthouse Financial preferred depositary shares, Series D, 4.625% Non-Cumulative) fails virtually every criterion I require for a concentrated, directional, catalyst-driven position. Let me be precise about what the fact base shows and why this is a hard avoid.

First, the tape is catastrophically against any long thesis. The price as of August 2, 2026 is $10.05 against a 52-week high of $66.80 — the stock (or preferred share) is sitting 85% below its 52-week high (fundamentals block: 'pct_below_52w_high: -84.96'). That is not a pullback to buy; that is a tape that is screaming distribution and structural impairment. I do not fight a tape like that.

Second, the earnings direction is not inflecting upward in any clean, readable way. GAAP net income for the common entity was $331M in FY2025 (10-K filed 2026-02-24) against a net loss of $1.214B in 2023, so there is recovery from a hole, but Q1 2026 showed a net loss available to shareholders of $792M (10-Q filed 2026-05-07), driven by 'unfavorable changes in variable annuity and Shield hedges.' The second derivative on GAAP earnings is turning sharply down again in the most recent quarter. Adjusted earnings of $239M in Q1 2026 vs $235M in Q1 2025 is essentially flat — no acceleration, no inflection worth sizing around.

Third, the balance sheet is opaque by design for an annuity-heavy insurer. Total assets of $241.8B against total liabilities of $234.967B leaves stockholders' equity of $6.768B (fundamentals block). The company has $19.7B of net ceded reinsurance recoverables with third-party reinsurers, of which $3.9B is unsecured (10-K 2026-02-24). The variable annuity guaranteed benefit riders (MRBs measured at fair value) create massive mark-to-market swings that make it impossible to cleanly read the earnings trajectory — exactly the kind of opacity that makes a directional macro bet unmanageable.

Fourth, and critically from a macro/liquidity standpoint: this is a rate-sensitive insurance company with massive ULSG interest rate exposure explicitly flagged in filings ('the primary market risk associated with our ULSG block is the uncertainty around the future levels of U.S. interest rates and bond yields,' 10-K 2026-02-24). The hedging program generates massive P&L volatility from rate moves, and the Q1 2026 loss primarily reflected hedge losses. There is no clean Fed tailwind thesis here.

Fifth, AM Best has placed the company 'Under Review with Negative Implications' (narrative digest, July 2026). A negative rating watch on an insurance company is a potential solvency/capital signal — the worst possible backdrop for a long position. This is a potential forced selling catalyst, not a buying one.

Sixth, BHFAM is a preferred share — 4.625% Non-Cumulative — trading at roughly $10 against what appears to be a par-related price dramatically higher. This is not a liquid leadership name I can size into and exit quickly with a clean thesis. There is no identifiable catalyst for price recovery in a non-cumulative preferred when the underlying entity is under rating review.

AI disruption is a secondary concern here — insurance distribution and annuity product design face some AI efficiency pressures, but this is not the primary risk. The primary risks are actuarial reserve adequacy, interest rate sensitivity, and capital adequacy, all of which are flashing red.

The thesis is broken at every level: tape, fundamentals direction, macro setup, balance sheet readability, and liquidity profile. Score: 18.

Key points

• Tape is catastrophically negative: BHFAM trading 85% below its 52-week high of $66.80 (fundamentals block) — textbook distribution, not accumulation
• Q1 2026 GAAP net loss of $792M (10-Q filed 2026-05-07) driven by variable annuity and Shield hedge losses — second derivative on GAAP earnings sharply negative
• Adjusted earnings nearly flat: $239M in Q1 2026 vs $235M in Q1 2025 (10-Q filed 2026-05-07) — no earnings acceleration to ride
• AM Best 'Under Review with Negative Implications' (narrative digest) is a material negative catalyst, not a buy signal
• $19.7B ceded reinsurance recoverables with $3.9B unsecured (10-K 2026-02-24) adds counterparty tail risk that is unquantifiable from this fact base
• ULSG interest rate sensitivity creates massive, unmanageable P&L volatility — incompatible with a clean directional macro trade
• Non-cumulative preferred share structure means missed dividends are gone forever — no recovery mechanism if capital is stressed

Red flags

• Price 85% below 52-week high — tape is in freefall, never fight this kind of tape
• AM Best negative rating watch signals potential capital/solvency concerns at the operating subsidiary level
• Variable annuity MRBs at fair value create enormous mark-to-market swings that make the earnings trajectory unreadable and unmanageable
• Non-cumulative structure on preferred: if dividends are skipped, holders have no claim — asymmetry is entirely to the downside
• No identifiable catalyst for price recovery; management transition chatter (Guggenheim/Mark Walters per narrative) adds uncertainty without clarity
• GAAP net loss of $792M in Q1 2026 — most recent period heading wrong direction
• Balance sheet opacity (derivatives, embedded derivatives, MRBs, reinsurance recoverables) makes it impossible to define a clean invalidation point for a concentrated position

Peter Lynch — 🔴 avoid · 18/100 · medium confidence

Brighthouse Financial (BHFAM) is a complex variable annuity and life insurance company — not an understandable operating business with a traceable earnings-growth story. The 'story' cannot be explained in a sentence or two in a way that satisfies the Lynch test: reported GAAP net income swings wildly based on fair-value marks on variable annuity guaranteed benefit riders (GMxBs), derivative hedges, and interest rate movements — not on a repeatable operational formula. In 2021 net income was $1.55B; 2022 $3.78B; 2023 a loss of $1.21B; 2024 $286M; 2025 $331M (per fundamentals history). This is not earnings growth — it is accounting volatility driven by mark-to-market derivatives. Management itself uses a non-GAAP 'adjusted earnings' metric to separate the noise, but even that (Q1 2026 adjusted earnings of $239M) is not the kind of compounding EPS machine Lynch looks for. The category here is best described as a 'turnaround/cyclical' financial — a heavily liability-driven insurer with $234.97B in total liabilities against $241.8B in assets (10-K filed 2026-02-24), leaving book equity of only $6.77B. Debt-to-equity is 0.46 per the fundamentals block, but the real leverage risk is the $19.7B in net ceded reinsurance recoverables with third-party reinsurers, of which $3.9B is unsecured (10-K filed 2026-02-24) — a massive counterparty concentration. The price quoted in the fact base ($10.05) appears inconsistent with narrative references to $62-63 and 52-week range of $42.07-$66.80 (the $10.05 figure likely reflects the preferred depositary share BHFAM, a 4.625% non-cumulative preferred, not the common equity BHF — the council should note this discrepancy). Assessing BHFAM as a preferred depositary share rather than common equity, the Lynch PEG framework is entirely inapplicable — there is no EPS growth story in a fixed preferred instrument. Even if treating this as a proxy for the common equity (BHF), the reported P/E of 10.74x on wildly volatile GAAP earnings is meaningless, and there is no stable EPS growth rate to plug into a PEG calculation. The AM Best 'Under Review with Negative Implications' rating watch (per the narrative, 29 Jul 2026) is a serious red flag — credit deterioration at an insurer with massive guaranteed benefit liabilities and a complex hedge book is exactly the kind of opaque, hard-to-model risk Lynch avoids. Revenue CAGR is essentially flat (-0.52% over 3 years per fundamentals). Operating cash flow is only $259M on a $3.6B market cap, and FCF history is entirely missing from the fact base. AI/technology disruption is not a primary near-term factor for an annuity book-of-business runoff insurer, but digitization of annuity distribution and robo-advisory alternatives could pressure new sales volumes over a 5-10 year horizon. This is not a Lynch stock at any price.

Key points

• BHFAM is a preferred depositary share (4.625% non-cumulative, Series D) per the 8-K filings — the Lynch PEG framework does not apply to a fixed-income preferred instrument
• Even treating BHF common as the subject: GAAP net income swings from +$3.78B (2022) to -$1.21B (2023) to +$331M (2025) — no stable EPS growth rate exists for PEG calculation (fundamentals history)
• Management relies on non-GAAP 'adjusted earnings' to strip out derivative/MRB fair-value noise; Q1 2026 adjusted earnings $239M vs. GAAP net loss of $792M available to shareholders (10-Q filed 2026-05-07)
• $234.97B in total liabilities vs. $241.8B total assets — extreme financial leverage inherent to insurance model (10-K filed 2026-02-24)
• $19.7B net ceded reinsurance recoverables; $3.9B unsecured with top-5 reinsurers — massive counterparty concentration risk (10-K filed 2026-02-24)
• AM Best 'Under Review with Negative Implications' — potential credit downgrade flagged in narrative (29 Jul 2026); capital adequacy concerns unresolved
• Revenue CAGR of -0.52% over 3 years; no growth story present (fundamentals block)

Red flags

• Earnings completely unintelligible from a Lynch perspective — GAAP swings of billions year-to-year driven by derivative marks and MRB fair values, not operations
• Business story requires actuarial, derivative, and reinsurance expertise to evaluate — explicitly violates Lynch's 'understand what you own' principle
• AM Best negative rating watch signals potential solvency/capital adequacy deterioration — existential risk category for an insurer
• No traceable PEG: earnings base is either negative, near-zero GAAP, or non-GAAP adjusted; growth rate is undefined or negative
• Price anomaly: $10.05 closing price vs. $42-$67 52-week range suggests this is the preferred depositary share, not the common — council should verify the correct instrument being assessed
• Missing FCF data for all historical years — cannot assess cash generation quality
• Reinsurance counterparty concentration: $16.5B of $19.7B recoverables with just five reinsurers (84%) — a reinsurer failure could be catastrophic (10-K filed 2026-02-24)

Chuck Akre — abstained

Brighthouse Financial (BHFAM — the 4.625% Non-Cumulative Preferred Stock, Series D depositary shares) is a financial institution — specifically a life insurance and annuity company spun off from MetLife. My framework is explicitly designed for capital-light, cash-generative franchise businesses where I can measure durable ROE/ROIC on owners' capital driven by genuine business economics rather than balance-sheet leverage and actuarial reserve management. Brighthouse does not meet this threshold for engagement. Total assets are $241.8B against stockholders' equity of $6.8B (10-K, period 2025-12-31), meaning the balance sheet is levered roughly 36:1 — any apparent ROE (reported ~4.9% from fundamentals) is an artifact of that leverage structure and mark-to-market accounting on derivatives and policyholder liabilities, not a reflection of underlying business economics I can evaluate on my three-legged stool. GAAP net income swings violently: $1.55B in 2021, $3.78B in 2022, a loss of $1.21B in 2023, and only $286M/$331M in 2024/2025 (fundamentals history) — driven overwhelmingly by changes in fair value of variable annuity guaranteed benefit riders, derivatives, and embedded derivatives rather than operational earnings power. The company's own management uses 'adjusted earnings' as the primary performance metric precisely because GAAP income is so distorted by these non-cash mark-to-market swings. Free cash flow is listed as null across all reported periods. This is exactly the class of business — balance-sheet-driven, insurance reserving complexity, leverage-dependent — where I have explicitly said I do not stretch to force a verdict. AI disruption is not a material factor for this abstention decision; the fundamental style mismatch is the sole reason.

Key points

• Balance sheet leverage of ~36:1 (assets $241.8B vs. equity $6.8B per 10-K 2025-12-31) disqualifies ROE analysis under my framework — returns are entirely leverage-driven, not business-economics-driven
• GAAP net income is not a reliable earnings signal: swings from +$3.78B (2022) to -$1.21B (2023) to +$331M (2025) are primarily driven by fair-value changes in variable annuity GMxB riders and derivatives, not operational performance
• No free cash flow data available in any reported period — FCF-based compounding analysis, the core of my approach, is impossible
• Company itself relies on non-GAAP 'adjusted earnings' as primary metric (Q1 2026: adjusted earnings $239M vs. GAAP net loss of $792M per 10-Q filed 2026-05-07), signaling the accounting complexity that puts this outside my circle of competence
• BHFAM ticker specifically refers to the Series D preferred depositary shares — a fixed-income-like instrument with 4.625% non-cumulative dividend, fundamentally not a compounding equity instrument I would evaluate for long-term ownership

Red flags

• AM Best 'Under Review with Negative Implications' (narrative, July 2026) suggests potential credit/capital adequacy deterioration — a solvency signal in an already opaque balance sheet
• $19.7B in net ceded reinsurance recoverables with counterparty concentration risk (top 5 reinsurers = 84%, including $3.9B unsecured per 10-K 2025-12-31) creates hidden tail risk I cannot adequately assess
• Q1 2026 net loss of $792M available to shareholders driven by 'unfavorable changes in variable annuity and Shield hedges' (10-Q 2026-03-31) illustrates ongoing earnings volatility from derivative mark-to-market
• ULSG block carries material interest rate risk with insufficient assets risk explicitly flagged in 10-K risk factors — not a predictable, resilient franchise
• Style is fundamentally mismatched: insurance/annuity businesses require actuarial, credit, and regulatory expertise outside my framework

Warren Buffett — abstained

BHFAM (Brighthouse Financial depositary preferred shares representing a 1/1,000th interest in 4.625% Non-Cumulative Preferred Stock, Series D) sits squarely outside my circle of competence. Brighthouse Financial is a variable annuity and life insurance company whose economics are dominated by: (1) complex mark-to-market movements on guaranteed minimum benefit riders (GMxB/MRBs) measured at fair value per the 10-K and 10-Q filings; (2) large derivative books used to hedge ULSG and variable annuity exposures; and (3) policyholder liabilities that require actuarial estimation. The 10-Q filed 2026-05-07 shows a net loss to common shareholders of $792 million in Q1 2026 alongside 'adjusted earnings' of $239 million — a $1 billion+ gap driven by fair-value swings in derivatives and embedded derivatives. This is precisely the kind of opaque, mark-to-model financials I cannot reliably value or forecast a decade forward. Beyond comprehensibility, the economics are deeply unattractive by my criteria: ROE per the fundamentals block is ~4.9% on GAAP equity; net income has been wildly erratic ($3.775B in 2022, -$1.214B in 2023, $286M in 2024, $331M in 2025 per the history data); there is no identifiable durable moat in commodity annuity distribution; and the AM Best 'Under Review with Negative Implications' rating watch (per the narrative) signals potential capital adequacy stress. Additionally, BHFAM is a preferred depositary share instrument, not common equity — it is a fixed-income-like instrument yielding 4.625%, not a business ownership stake that compounds intrinsic value. The Buffett quality framework simply does not apply to this security or this business.

Key points

• BHFAM is a depositary preferred share (4.625% non-cumulative, Series D), not common equity — there is no compounding ownership stake to value on an owner-earnings basis
• Business model is dominated by variable annuity guaranteed benefit riders (GMxB/MRBs) measured at fair value with large mark-to-market swings; 10-Q (2026-05-07) shows $1B+ divergence between GAAP net loss and non-GAAP adjusted earnings in a single quarter
• Earnings history is violently erratic: $3.775B net income in 2022, -$1.214B in 2023, $286M in 2024, $331M in 2025 (per fundamentals history) — no consistent, predictable earnings record
• ROE of ~4.9% (fundamentals block) is far below my 15%+ sustained threshold, and is achieved on a balance sheet with $234.97B in liabilities against $6.77B equity (10-K filed 2026-02-24)
• AM Best 'Under Review with Negative Implications' (narrative) is a material credit concern, not a signal of fortress balance sheet strength
• Valuation block itself flags DCF inapplicable for insurers — P/B of 0.53x is cheap optically but meaningless without confidence in the book value quality given mark-to-model liabilities

Red flags

• Complex derivatives and embedded derivatives make economics impossible to forecast reliably — this is outside my circle of competence
• Non-cumulative preferred: dividends can be skipped without triggering default, limiting downside protection
• Reinsurance concentration: $16.5B of $19.7B net ceded recoverables with five largest reinsurers, including $3.9B unsecured (10-K filed 2026-02-24) — counterparty risk embedded in the balance sheet
• Erratic GAAP earnings driven by fair-value accounting on guaranteed benefit riders render normalized owner-earnings calculation impossible
• AM Best negative rating watch suggests regulatory/capital adequacy scrutiny is live

Valuation Referee (Damodaran-style) — abstained

BHFAM is a depositary share representing a 1/1,000th interest in Brighthouse Financial's 4.625% Non-Cumulative Preferred Stock, Series D (confirmed in the 8-K filings dated 2026-06-03 and 2026-05-06). This is a fixed-income-like preferred equity instrument, not a common equity claim on the company's cash flows. A Damodaran-style story-to-numbers DCF — built on revenue growth, target operating margins, reinvestment (sales-to-capital ratio), and WACC converging to a terminal steady state — is fundamentally inapplicable here. The 'value' of a non-cumulative preferred depositary share is driven by its stated dividend yield (4.625% on liquidation preference), credit quality of the issuer, call provisions, and the spread over risk-free rates — not by forecast free cash flows to the firm or equity. Furthermore, the valuation block in the fact base explicitly flags that FCF-based DCF is 'not appropriate for Insurance — banks/insurers are valued on P/B and ROE.' Compounding this, the AM Best 'Under Review with Negative Implications' noted in the narrative digest raises credit-quality concerns directly relevant to preferred dividend security, but this is a credit/spread analysis, not a DCF exercise. Applying a FCFF or FCFE model here would be false precision on an instrument whose value is determined by entirely different mechanics. The honest verdict is to abstain rather than force an inapplicable framework onto a preferred security of an insurance holding company.

Key points

• BHFAM is a depositary preferred share (4.625% Non-Cumulative, Series D), not common equity — confirmed in multiple SEC filings (8-K 2026-06-03, 8-K 2026-05-06)
• DCF valuation is explicitly flagged not-applicable in the fact base's valuation block for insurance companies
• Preferred share value is a function of stated coupon, credit quality, call risk, and spread over risk-free rate — not forecast FCF
• AM Best 'Under Review with Negative Implications' (narrative digest, 29 Jul 2026) is the key risk for preferred holders but requires credit analysis, not DCF
• No margin-of-safety or intrinsic-value conclusion is derivable without a defensible cash-flow model

Red flags

• AM Best negative rating watch signals potential credit deterioration — directly threatens preferred dividend security
• Non-cumulative structure means skipped dividends are never recovered — asymmetric downside for preferred holders
• Q1 2026 10-Q shows net loss available to common shareholders of $792 million for the quarter, driven by hedge losses on variable annuity and Shield products — signals earnings volatility
• Large reinsurance concentration risk: $16.5 billion (84%) of $19.7 billion net ceded recoverables held with five largest reinsurers, including $3.9 billion unsecured (10-K filed 2026-02-24)
• Applying a DCF framework to this instrument would constitute false precision — the correct tool is a credit/spread model outside this lens's mandate

Philip Fisher — abstained

Brighthouse Financial (BHFAM) is a variable annuity and life insurance company — a mature, capital-intensive financial institution whose economics are driven by actuarial assumptions, interest rate spreads, reserve adequacy, and regulatory capital ratios. There is no R&D pipeline, no product innovation runway in the Fisher sense, no volume-driven organic sales growth story, and no scuttlebutt-accessible franchise quality to assess. Revenue CAGR per the fact base is essentially flat at -0.5% over three years (fundamentals block). Net income is wildly volatile — $3.8B in 2022, -$1.2B in 2023, $286M in 2024, $331M in 2025 (fundamentals history) — driven almost entirely by mark-to-market moves on derivatives, variable annuity guaranteed benefit riders, and interest rate sensitivities, not by any durable product/market expansion. The 10-K (filed 2026-02-24) makes clear that earnings swings are dominated by fair-value changes in MRBs and ULSG interest rate derivatives, not by management's ability to build a compounding franchise. My school requires sustained above-average organic sales growth driven by R&D and new products, a visible multi-year runway, and management reinvesting at high returns into an expanding market. None of these conditions exist here. This is a run-off/mature insurance liability manager, not a growth business. Stretching my framework to render a verdict would produce a meaningless or misleading score.

Key points

• Revenue CAGR of approximately -0.5% over three years (fundamentals block) — no organic growth trajectory
• Net income volatility is actuarial/derivative-driven, not franchise-driven: swings from +$3.8B to -$1.2B to +$331M in three years
• No R&D spend, no product pipeline, no new market expansion identifiable in SEC filings
• Business model is liability management of a fixed annuity/variable annuity/ULSG block — structural runoff characteristics
• Fisher's scuttlebutt method and growth criteria simply have no surface area to grip on this business

Red flags

• AM Best 'Under Review with Negative Implications' (narrative, 29 Jul 2026) — capital/solvency concern that is directly contrary to the financial strength Fisher requires in a long-term compounder
• 52-week price range of $42.07–$66.80 against current price of $10.05 raises serious questions about a possible ticker mismatch or data anomaly in the fact base — BHFAM appears to be a preferred depositary share series, not the common equity, making any growth-equity analysis doubly inapplicable
• Earnings dominated by uncontrollable mark-to-market swings rather than management-driven compounding

Joel Greenblatt — abstained

Brighthouse Financial (BHFAM) is an insurance holding company — precisely the category Greenblatt explicitly excludes from the Magic Formula and special-situations ROIC analysis. The reason is fundamental, not peripheral: (1) EV is not meaningful for an insurer because policyholder liabilities (totaling ~$234.97 billion per the 2025 10-K) are not financial debt in the conventional sense, and separating 'operating' from 'financing' liabilities is impossible; (2) ROIC as EBIT/(NWC + net fixed assets) is nonsensical — the balance sheet is dominated by investment portfolios, reinsurance recoverables ($19.7 billion per the 2025 10-K), market risk benefit reserves, and embedded derivative liabilities, not the tangible working capital and fixed assets that Greenblatt's denominator requires; (3) reported 'EBIT' is thoroughly contaminated by mark-to-market swings on variable annuity guaranteed benefit riders (MRBs measured at fair value) and derivative gains/losses — the 10-Q for Q1 2026 shows a GAAP net loss of $792 million alongside 'adjusted earnings' of $239 million for the same quarter, a $1 billion gap driven entirely by hedging and fair-value movements that have no analog to the repeatable operating earnings the formula demands; (4) the company itself uses a non-GAAP 'adjusted earnings' metric because GAAP earnings are so distorted by these insurance-specific items as to be nearly unanalyzable for Magic Formula purposes. There is no credible special-situation angle either — the spinoff from MetLife occurred in 2017 and the forced-selling dynamic is long past. The AM Best 'Under Review with Negative Implications' rating action (per the narrative, dated July 29, 2026) introduces credit/solvency uncertainty that makes this even less analyzable. Attempting to force ROIC and earnings yield calculations on this entity would be fabricating inputs rather than measuring real economics — the single worst failure mode per my methodology.

Key points

• Insurer balance sheet with $241.8B total assets and $234.97B total liabilities (2025 10-K) dominated by policyholder reserves and investment portfolios — EV construction is not meaningful
• ROIC denominator (NWC + net fixed assets) cannot be derived; tangible capital in the Greenblatt sense does not exist for an insurance holding company
• GAAP EBIT is polluted by mark-to-market on MRBs and derivatives — Q1 2026 shows $792M GAAP net loss vs. $239M adjusted earnings (10-Q filed 2026-05-07), a gap exceeding $1B in a single quarter
• No live special-situation catalyst; MetLife spinoff is ~9 years old
• AM Best negative rating watch (per narrative, July 2026) adds solvency uncertainty that further undermines any capital-adequacy assessment

Red flags

• Financial/insurance company — explicitly outside Magic Formula applicability
• Mark-to-market earnings volatility makes normalized EBIT uncomputable without deep actuarial expertise
• $19.7B ceded reinsurance recoverables with $3.9B unsecured (2025 10-K) represent hidden counterparty risk not visible in ROIC
• Negative GAAP earnings in Q1 2026 and FY2023 ($-1.214B) signal extreme earnings instability
• AM Best 'Under Review with Negative Implications' is a potential credit-quality deterioration signal

Bruce Greenwald — abstained

BHFAM (Brighthouse Financial) is a large-scale insurance holding company — primarily a variable annuity and life insurance writer. The EPV/asset-reproduction framework I use is fundamentally not applicable here. Insurance companies do not have 'operating earnings' that can be cleanly normalized and capitalized in the manner EPV requires: reported GAAP net income swings wildly with mark-to-market movements on variable annuity guaranteed benefit riders (MRBs), derivative hedging gains/losses on ULSG, and actuarial reserve changes — all of which are non-cash, non-operational, and not reflective of underlying earnings power. The 10-K (filed 2026-02-24) confirms this: 2021 net income was $1.554B, 2022 was $3.775B, 2023 was -$1.214B, 2024 was $286M, 2025 was $331M — a five-year range of nearly $5B, entirely driven by derivative and MRB fair-value swings rather than operating performance. The 10-Q (filed 2026-05-07, period ending 2026-03-31) shows Q1 2026 net loss of $792M against adjusted earnings of $239M — the gap is almost entirely hedging noise. Even management's own non-GAAP 'adjusted earnings' metric strips out these items, acknowledging that GAAP income is not the right earnings concept. Asset reproduction value is equally inapplicable: Brighthouse's $241.8B balance sheet (fundamentals, period 2025-12-31) consists overwhelmingly of investment portfolios and policyholder liabilities — these are financial assets/liabilities that cannot be analyzed through a 'cost to reproduce' lens the way a manufacturer's plant, distribution network, or customer base can be. The valuation block in the fact base explicitly flags: 'FCF-based DCF is not appropriate for Insurance — banks/insurers are valued on P/B and ROE.' The correct analytical frame for Brighthouse is P/B vs. ROE (book value $6.768B, price-to-book ~0.53x per fundamentals), statutory capital adequacy, and spread/margin analysis — none of which are my tools. Abstaining is the only intellectually honest verdict; forcing an EPV analysis here would produce meaningless numbers and potentially misleading conclusions.

Key points

• EPV normalization is impossible: GAAP net income ranges from -$1.2B to +$3.8B over five years (10-K 2026-02-24 and fundamentals history), driven entirely by MRB and derivative fair-value movements, not operating performance
• The company itself uses non-GAAP 'adjusted earnings' to strip out these distortions, confirming GAAP income is not a stable earnings-power figure
• Asset reproduction value framework does not apply to a $241.8B financial balance sheet of investment securities and insurance liabilities (fundamentals, 2025-12-31)
• Valuation block explicitly flags DCF as not applicable for insurance; P/B and ROE are the appropriate metrics for this sector
• AM Best 'Under Review with Negative Implications' (narrative, 29 Jul 2026) is a relevant capital/solvency signal that would matter under a P/B/statutory capital lens, not an EPV lens

Red flags

• Attempting to apply EPV to an insurance company would require normalizing earnings that are structurally non-normalizable under GAAP — any resulting number would be fabricated precision
• No earnings call transcript available (narrative confirms this), so even adjusted earnings trends cannot be fully assessed
• AM Best negative review watch signals potential statutory capital concerns that are material but require an insurance-specific analytical framework to evaluate properly

Charlie Munger — abstained

Brighthouse Financial is a complex variable annuity and life insurance holding company whose economics are fundamentally outside the Munger circle of competence as I define it. The business model is a financial black box: net income swings from +$3.8B in 2022 to -$1.2B in 2023 to +$331M in 2025 (per fundamentals history), driven not by operating performance but by mark-to-market changes in variable annuity guaranteed benefit riders (GMxBs), embedded derivatives, and interest rate hedges on ULSG liabilities. The 10-K and 10-Q filings confirm that GAAP net income is dominated by fair-value movements in market risk benefits and derivative instruments that are nearly impossible for an outsider to predict or trust as a proxy for owner earnings. Management itself disavows GAAP net income as the primary performance measure, substituting non-GAAP 'adjusted earnings' — a strong signal that reported earnings are not a reliable guide to intrinsic value. The Q1 2026 10-Q shows a net loss available to shareholders of $792 million against adjusted earnings of $239 million — a $1 billion divergence in a single quarter. There is no identifiable durable moat: variable annuities are commoditized products distributed through broker-dealers with low switching costs for the distribution channel, and the company competes on crediting rates and product features rather than brand or pricing power. The balance sheet is extreme financial leverage — $235B in liabilities against $6.8B equity (10-K filed 2026-02-24) — with $19.7B of net ceded reinsurance recoverables concentrated among five reinsurers, including $3.9B unsecured (10-K filed 2026-02-24). The AM Best 'Under Review with Negative Implications' rating action noted in the narrative digest adds a live solvency signal. ROE of 4.9% on reported earnings is far below my 15% quality threshold, and the adjusted earnings figure is not audited in a form I can trust from the outside. This is precisely the kind of complex financial institution Munger has explicitly said he cannot value and will not own. Inversion: this could impair capital permanently through a severe equity market downturn triggering massive GMxB reserve increases, a reinsurer default on the concentrated $3.9B unsecured exposure, or a credit downgrade cascading into surrenders. I see obvious fatal answers to my inversion test. Abstaining entirely.

Key points

• Business model is a financial black box driven by mark-to-market fair-value accounting on derivatives and guaranteed benefit riders — not understandable operating economics
• GAAP net income is wildly volatile and disavowed by management in favor of non-GAAP adjusted earnings — Q1 2026 shows $1B divergence between the two in a single quarter (10-Q filed 2026-05-07)
• No identifiable durable moat: variable annuities are commoditized, distributed through intermediaries, competing on price/features rather than brand or pricing power
• ROE of ~4.9% on reported earnings vastly below Munger's 15%+ quality threshold; adjusted earnings ROE not verifiable from public filings in a clean form
• Extreme financial leverage: $234.9B liabilities vs $6.8B equity per 10-K filed 2026-02-24; $19.7B reinsurance recoverables with $3.9B unsecured concentration risk
• AM Best negative rating watch per narrative digest — live signal of potential capital adequacy stress
• Stock price discrepancy: narrative references ~$62-63 while price block shows $10.05 — suggests BHFAM is a preferred/depositary share instrument, not the common equity BHF, making the analysis even less straightforward

Red flags

• Outside circle of competence: complex derivatives, GMxB fair-value accounting, actuarial reserve estimates — cannot reliably assess intrinsic value
• GAAP earnings not a trustworthy proxy for owner earnings; heavy reliance on non-GAAP adjusted earnings
• Inversion test fails: severe equity market crash, reinsurer default, or rating downgrade could cause permanent capital impairment
• AM Best Under Review with Negative Implications — potential downgrade of insurance subsidiaries
• Concentrated reinsurance credit risk: $3.9B unsecured with top-5 reinsurers (10-K filed 2026-02-24)
• Revenue CAGR of -0.5% over 3 years per fundamentals — no organic growth to speak of
• No evidence of durable reinvestment runway at high incremental returns — essential for Munger-style compounding

Terry Smith (Fundsmith) — abstained

Brighthouse Financial (BHFAM) is an insurance holding company — specifically a writer of variable annuities, Shield annuities, and universal life products. This is precisely the capital-intensive, financially opaque, leveraged financial institution category that Terry Smith explicitly excludes from the Fundsmith universe. The Fundsmith quality screen cannot be meaningfully applied here for multiple structural reasons: (1) The DCF/FCF framework is inapplicable — the valuation block explicitly flags this, noting FCF-based analysis does not work for insurers, which are correctly valued on P/B and ROE. Free cash flow data is listed as null across all historical years in the fact base. (2) ROCE cannot be computed in the conventional sense — the balance sheet shows total assets of $241.8bn against stockholders' equity of $6.77bn (10-K filed 2026-02-24), a leverage ratio characteristic of financial institutions where policyholder liabilities (not productive capital) dominate the asset base. This structure is fundamentally incompatible with the pre-tax ROCE > 20% test Smith applies. (3) Earnings are highly volatile and driven by mark-to-market movements on derivatives and embedded guarantee liabilities rather than underlying operating cash generation — the 10-Q (filed 2026-05-07) shows a net loss of $792m in Q1 2026 against GAAP-adjusted earnings of $239m, with the divergence driven by variable annuity hedge movements. This is precisely the 'adjusted earnings masking reality' pattern Smith distrusts. (4) The business is capital-intensive in the insurance sense — it must hold large statutory reserves, faces material interest rate and equity market sensitivity in its ULSG and GMxB blocks, and relies heavily on reinsurance ($19.7bn net ceded recoverables per the 2025 10-K). (5) Demand is not recurring-consumable; it is episodic, rate-sensitive, and regulated. There is no pricing power moat of the kind Smith values. Attempting to apply Fundsmith criteria here would be methodologically dishonest — I abstain entirely.

Key points

• Insurance/annuity business is explicitly outside the Fundsmith investable universe — same category as banks, utilities, and capital-intensive financials that Smith openly excludes
• FCF data is null across all historical years in the fact base; the valuation block confirms FCF-based DCF is inapplicable for this business model
• Total assets of $241.8bn vs. equity of $6.77bn (10-K 2026-02-24) reflects insurer leverage, not the asset-light, self-funding model Fundsmith requires
• GAAP net income swings wildly — loss of $1.214bn in 2023, profit of $286m in 2024, $331m in 2025, loss of $792m in Q1 2026 alone (10-Q 2026-05-07) — driven by derivative mark-to-market, not operational performance
• The quality screen (sustained ROCE >20%, high margins, strong cash conversion, light capex) simply has no traction on a balance sheet dominated by policyholder liabilities and reinsurance recoverables

Red flags

• AM Best 'Under Review with Negative Implications' (narrative, July 2026) — signals potential capital/reserve adequacy concerns, the opposite of Fundsmith's financial strength requirement
• $19.7bn in net ceded reinsurance recoverables with $3.9bn unsecured (10-K 2026-02-24) — concentrated counterparty exposure incompatible with balance sheet quality standards
• Earnings heavily reliant on non-GAAP 'adjusted earnings' metric; management explicitly uses this to bridge a gap to GAAP results that are dominated by derivative noise — exactly the adjusted-earnings-masking-reality pattern Smith distrusts
• Revenue CAGR of -0.52% over 3 years (fundamentals block) — not the compounding growth engine Fundsmith seeks
• Stock is trading at $10.05 against a 52-week high of $66.80 — an 85% collapse that likely reflects structural concerns, not a temporary dislocation a quality buyer would exploit

---

Fact base appendix

Price

• last_close: 10.05
• as_of: 2026-08-02
• high_52w: 66.8
• low_52w: 42.07
• range_source: provider
• pct_below_52w_high: -84.96

Fundamentals

• last_price: 10.05
• market_cap: 3556468624
• fifty_two_week_high: 66.8
• fifty_two_week_low: 42.07
• beta: 0.87140113
• currency: USD
• exchange: NASDAQ NMS - GLOBAL MARKET
• sector: Insurance
• industry: Insurance
• price_source: finnhub
• bars: 1
• entity: Brighthouse Financial, Inc.
• fiscal_year: 2025
• revenue: 6766000000
• revenue_period: 2025-12-31
• net_income: 331000000
• net_income_period: 2025-12-31
• operating_cash_flow: 259000000
• operating_cash_flow_period: 2025-12-31
• total_assets: 241800000000
• total_assets_period: 2025-12-31
• total_liabilities: 234967000000
• total_liabilities_period: 2025-12-31
• stockholders_equity: 6768000000
• stockholders_equity_period: 2025-12-31
• long_term_debt: 3155000000
• long_term_debt_period: 2025-12-31
• shares_outstanding: 57184099
• operating_margin: None
• net_margin: 0.0489
• roe: 0.0489
• debt_to_equity: 0.4662
• current_ratio: None
• pe_ratio: 10.74
• price_to_sales: 0.53
• revenue_cagr: -0.0052
• revenue_cagr_years: 3
• fundamentals_source: edgar_companyfacts
• price_to_book: 0.53

Filings reviewed

• 8-K (2026-06-03) https://www.sec.gov/Archives/edgar/data/1685040/000168504026000022/bhf-20260603.htm
• 10-Q (2026-05-07) https://www.sec.gov/Archives/edgar/data/1685040/000168504026000019/bhf-20260331.htm
• 8-K (2026-05-06) https://www.sec.gov/Archives/edgar/data/1685040/000168504026000017/bhf-20260506.htm
• 10-K (2026-02-24) https://www.sec.gov/Archives/edgar/data/1685040/000168504026000011/bhf-20251231.htm
• 10-Q (2025-11-07) https://www.sec.gov/Archives/edgar/data/1685040/000168504025000071/bhf-20250930.htm
• 10-K (2025-02-28) https://www.sec.gov/Archives/edgar/data/1685040/000168504025000010/bhf-20241231.htm

Other sources

• [news] AM Best Maintains Under Review With Negative Implications Status for Brighthouse Financial, Inc. and Its Subsidiaries - Business Wire
• [news] ETFs Investing in Brighthouse Financial, Inc. Depositary Shs Repr 1/1000th 4.625 % Non-Cum Red Perp Pfd Rg Shs Series -D- Stocks - TradingView
• [news] Brighthouse Financial - Forbes
• [news] Should You Buy Brighthouse Financial, Inc. (BHF)’s Shares? - finance.yahoo.com
• [news] BHF|Brighthouse Financial Inc|Price:62.940|Chg%:-0.810 - TradingKey
• [news] Brighthouse Financial edges lower amid reports about Mark Walters, Guggenheim \ - Seeking Alpha
• [news] Brighthouse Financial (BHF) to Report Q2 Results: Wall Street Expects Earnings Growth - finance.yahoo.com
• [news] BHF|Brighthouse Financial Inc|Price:61.950|Chg%:-1.500 - TradingKey
• [news] Brighthouse Financial Inc (BHF) Valuation: PE, PB & Fair Value Analysis - TradingKey
• [news] BHF Forecast — Price Target — Prediction for 2027 - TradingView
• [news] Price to earnings forward of Brighthouse Financial, Inc. - depositary shares, each representing a 1/1,000th interest in a share of 5.375% Non-Cumulative Preferred Stock, Series C – BOATS:BHFAN - TradingView
• [news] Brighthouse Financial (BHF) Proxy Filing Summary - Quartr
• [news] Implied Volatility Surging for Brighthouse Financial Stock Options - finance.yahoo.com
• [news] Enterprise value to revenue forward of Brighthouse Financial, Inc. – NASDAQ:BHF - TradingView
• [news] Brighthouse Financial, Inc. Actuals & Estimates (LS:A2DUDM) - TradingView
• [news] Brighthouse Financial, Inc. Depositary Shs Repr 1/1000th 5.375% Non-Cum Red Perp Pfd Rg ShsSeries C Actuals & Estimates (NASDAQ:BHFAN) - TradingView
• [news] Brighthouse Financial, Inc. Revenue Breakdown – NASDAQ:BHF - TradingView
• [news] Brighthouse Financial Inc expected to post earnings of $4.86 a share - Earnings Preview - TradingView

Data gaps

• Dataset completeness: 18 of 18 source documents were dropped to fit the prompt budget — the council did not see them.

---

Generated 2026-08-02T16:50:58 · est. cost $0.86